WO1999066958A2 - Utilisation d'un compose possedant une affinite pour le recepteur mitochondrial des benzodiazepines en therapie du cancer - Google Patents
Utilisation d'un compose possedant une affinite pour le recepteur mitochondrial des benzodiazepines en therapie du cancer Download PDFInfo
- Publication number
- WO1999066958A2 WO1999066958A2 PCT/FR1999/001383 FR9901383W WO9966958A2 WO 1999066958 A2 WO1999066958 A2 WO 1999066958A2 FR 9901383 W FR9901383 W FR 9901383W WO 9966958 A2 WO9966958 A2 WO 9966958A2
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- group
- phenyl
- alkyl
- carbon atoms
- apoptosis
- Prior art date
Links
- 150000001875 compounds Chemical class 0.000 title claims abstract description 62
- 230000002438 mitochondrial effect Effects 0.000 title abstract description 17
- SVUOLADPCWQTTE-UHFFFAOYSA-N 1h-1,2-benzodiazepine Chemical compound N1N=CC=CC2=CC=CC=C12 SVUOLADPCWQTTE-UHFFFAOYSA-N 0.000 title abstract description 3
- 229940049706 benzodiazepine Drugs 0.000 title abstract description 3
- 238000011275 oncology therapy Methods 0.000 title description 3
- 230000006907 apoptotic process Effects 0.000 claims abstract description 53
- 239000003795 chemical substances by application Substances 0.000 claims abstract description 25
- 206010028980 Neoplasm Diseases 0.000 claims abstract description 17
- 230000001939 inductive effect Effects 0.000 claims abstract description 15
- 201000011510 cancer Diseases 0.000 claims abstract description 13
- 239000003814 drug Substances 0.000 claims abstract description 10
- 239000013066 combination product Substances 0.000 claims abstract description 6
- 229940127555 combination product Drugs 0.000 claims abstract description 6
- 229910052757 nitrogen Inorganic materials 0.000 claims description 54
- 125000000217 alkyl group Chemical group 0.000 claims description 34
- 239000000047 product Substances 0.000 claims description 30
- 125000004432 carbon atom Chemical group C* 0.000 claims description 28
- -1 pyridyl radical Chemical group 0.000 claims description 27
- 125000004433 nitrogen atom Chemical group N* 0.000 claims description 24
- 238000011282 treatment Methods 0.000 claims description 19
- 125000000753 cycloalkyl group Chemical group 0.000 claims description 17
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 claims description 16
- 125000005843 halogen group Chemical group 0.000 claims description 16
- 230000006882 induction of apoptosis Effects 0.000 claims description 16
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 15
- AOJJSUZBOXZQNB-TZSSRYMLSA-N Doxorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 AOJJSUZBOXZQNB-TZSSRYMLSA-N 0.000 claims description 14
- 125000003545 alkoxy group Chemical group 0.000 claims description 14
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims description 14
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 claims description 14
- LKJPYSCBVHEWIU-UHFFFAOYSA-N N-[4-cyano-3-(trifluoromethyl)phenyl]-3-[(4-fluorophenyl)sulfonyl]-2-hydroxy-2-methylpropanamide Chemical compound C=1C=C(C#N)C(C(F)(F)F)=CC=1NC(=O)C(O)(C)CS(=O)(=O)C1=CC=C(F)C=C1 LKJPYSCBVHEWIU-UHFFFAOYSA-N 0.000 claims description 12
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 claims description 12
- 239000003446 ligand Substances 0.000 claims description 11
- 108090000623 proteins and genes Proteins 0.000 claims description 11
- 102100031274 Translocator protein Human genes 0.000 claims description 10
- 101710166801 Translocator protein Proteins 0.000 claims description 10
- 125000001424 substituent group Chemical group 0.000 claims description 10
- YDNKGFDKKRUKPY-JHOUSYSJSA-N C16 ceramide Natural products CCCCCCCCCCCCCCCC(=O)N[C@@H](CO)[C@H](O)C=CCCCCCCCCCCCCC YDNKGFDKKRUKPY-JHOUSYSJSA-N 0.000 claims description 9
- CRJGESKKUOMBCT-VQTJNVASSA-N N-acetylsphinganine Chemical compound CCCCCCCCCCCCCCC[C@@H](O)[C@H](CO)NC(C)=O CRJGESKKUOMBCT-VQTJNVASSA-N 0.000 claims description 9
- 229940106189 ceramide Drugs 0.000 claims description 9
- ZVEQCJWYRWKARO-UHFFFAOYSA-N ceramide Natural products CCCCCCCCCCCCCCC(O)C(=O)NC(CO)C(O)C=CCCC=C(C)CCCCCCCCC ZVEQCJWYRWKARO-UHFFFAOYSA-N 0.000 claims description 9
- 238000004519 manufacturing process Methods 0.000 claims description 9
- VVGIYYKRAMHVLU-UHFFFAOYSA-N newbouldiamide Natural products CCCCCCCCCCCCCCCCCCCC(O)C(O)C(O)C(CO)NC(=O)CCCCCCCCCCCCCCCCC VVGIYYKRAMHVLU-UHFFFAOYSA-N 0.000 claims description 9
- 125000000636 p-nitrophenyl group Chemical group [H]C1=C([H])C(=C([H])C([H])=C1*)[N+]([O-])=O 0.000 claims description 8
- VJJPUSNTGOMMGY-MRVIYFEKSA-N etoposide Chemical compound COC1=C(O)C(OC)=CC([C@@H]2C3=CC=4OCOC=4C=C3[C@@H](O[C@H]3[C@@H]([C@@H](O)[C@@H]4O[C@H](C)OC[C@H]4O3)O)[C@@H]3[C@@H]2C(OC3)=O)=C1 VJJPUSNTGOMMGY-MRVIYFEKSA-N 0.000 claims description 7
- 229960005420 etoposide Drugs 0.000 claims description 7
- 239000001257 hydrogen Substances 0.000 claims description 7
- 229910052739 hydrogen Inorganic materials 0.000 claims description 7
- 229910052760 oxygen Inorganic materials 0.000 claims description 7
- 239000001301 oxygen Substances 0.000 claims description 7
- 125000003884 phenylalkyl group Chemical group 0.000 claims description 7
- 125000006273 (C1-C3) alkyl group Chemical group 0.000 claims description 6
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 claims description 6
- 125000004207 3-methoxyphenyl group Chemical group [H]C1=C([H])C(*)=C([H])C(OC([H])([H])[H])=C1[H] 0.000 claims description 6
- RWRDLPDLKQPQOW-UHFFFAOYSA-N Pyrrolidine Chemical compound C1CCNC1 RWRDLPDLKQPQOW-UHFFFAOYSA-N 0.000 claims description 6
- 229910052794 bromium Inorganic materials 0.000 claims description 6
- 229960004679 doxorubicin Drugs 0.000 claims description 6
- 230000000861 pro-apoptotic effect Effects 0.000 claims description 6
- 125000001544 thienyl group Chemical group 0.000 claims description 6
- 210000004881 tumor cell Anatomy 0.000 claims description 6
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims description 5
- 125000003342 alkenyl group Chemical group 0.000 claims description 5
- 239000000460 chlorine Substances 0.000 claims description 5
- 229910052801 chlorine Inorganic materials 0.000 claims description 5
- 125000004076 pyridyl group Chemical group 0.000 claims description 5
- 125000004178 (C1-C4) alkyl group Chemical group 0.000 claims description 4
- WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical compound [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 claims description 4
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 claims description 4
- 108020004414 DNA Proteins 0.000 claims description 4
- RAVIZVQZGXBOQO-UHFFFAOYSA-N PK-11195 Chemical compound N=1C(C(=O)N(C)C(C)CC)=CC2=CC=CC=C2C=1C1=CC=CC=C1Cl RAVIZVQZGXBOQO-UHFFFAOYSA-N 0.000 claims description 4
- 125000000304 alkynyl group Chemical group 0.000 claims description 4
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 claims description 4
- 125000005605 benzo group Chemical group 0.000 claims description 4
- GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Substances BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 claims description 4
- 229910052731 fluorine Inorganic materials 0.000 claims description 4
- 125000005842 heteroatom Chemical group 0.000 claims description 4
- 229910052717 sulfur Inorganic materials 0.000 claims description 4
- MYMOFIZGZYHOMD-UHFFFAOYSA-N Dioxygen Chemical compound O=O MYMOFIZGZYHOMD-UHFFFAOYSA-N 0.000 claims description 3
- 102000003676 Glucocorticoid Receptors Human genes 0.000 claims description 3
- 108090000079 Glucocorticoid Receptors Proteins 0.000 claims description 3
- 108020004440 Thymidine kinase Proteins 0.000 claims description 3
- 125000004429 atom Chemical group 0.000 claims description 3
- 230000034994 death Effects 0.000 claims description 3
- UREBDLICKHMUKA-CXSFZGCWSA-N dexamethasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@@H](C)[C@@](C(=O)CO)(O)[C@@]1(C)C[C@@H]2O UREBDLICKHMUKA-CXSFZGCWSA-N 0.000 claims description 3
- 239000003862 glucocorticoid Substances 0.000 claims description 3
- 229910052740 iodine Inorganic materials 0.000 claims description 3
- ZPYGDHPQNREYNO-UHFFFAOYSA-N isoquinoline;propanamide Chemical compound CCC(N)=O.C1=NC=CC2=CC=CC=C21 ZPYGDHPQNREYNO-UHFFFAOYSA-N 0.000 claims description 3
- 229960003538 lonidamine Drugs 0.000 claims description 3
- WDRYRZXSPDWGEB-UHFFFAOYSA-N lonidamine Chemical compound C12=CC=CC=C2C(C(=O)O)=NN1CC1=CC=C(Cl)C=C1Cl WDRYRZXSPDWGEB-UHFFFAOYSA-N 0.000 claims description 3
- 125000004434 sulfur atom Chemical group 0.000 claims description 3
- RCINICONZNJXQF-MZXODVADSA-N taxol Chemical compound O([C@@H]1[C@@]2(C[C@@H](C(C)=C(C2(C)C)[C@H](C([C@]2(C)[C@@H](O)C[C@H]3OC[C@]3([C@H]21)OC(C)=O)=O)OC(=O)C)OC(=O)[C@H](O)[C@@H](NC(=O)C=1C=CC=CC=1)C=1C=CC=CC=1)O)C(=O)C1=CC=CC=C1 RCINICONZNJXQF-MZXODVADSA-N 0.000 claims description 3
- 125000004455 (C1-C3) alkylthio group Chemical group 0.000 claims description 2
- FDKXTQMXEQVLRF-ZHACJKMWSA-N (E)-dacarbazine Chemical compound CN(C)\N=N\c1[nH]cnc1C(N)=O FDKXTQMXEQVLRF-ZHACJKMWSA-N 0.000 claims description 2
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 claims description 2
- CMSMOCZEIVJLDB-UHFFFAOYSA-N Cyclophosphamide Chemical compound ClCCN(CCCl)P1(=O)NCCCO1 CMSMOCZEIVJLDB-UHFFFAOYSA-N 0.000 claims description 2
- PXGOKWXKJXAPGV-UHFFFAOYSA-N Fluorine Chemical compound FF PXGOKWXKJXAPGV-UHFFFAOYSA-N 0.000 claims description 2
- FBOZXECLQNJBKD-ZDUSSCGKSA-N L-methotrexate Chemical compound C=1N=C2N=C(N)N=C(N)C2=NC=1CN(C)C1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 FBOZXECLQNJBKD-ZDUSSCGKSA-N 0.000 claims description 2
- ZDZOTLJHXYCWBA-VCVYQWHSSA-N N-debenzoyl-N-(tert-butoxycarbonyl)-10-deacetyltaxol Chemical compound O([C@H]1[C@H]2[C@@](C([C@H](O)C3=C(C)[C@@H](OC(=O)[C@H](O)[C@@H](NC(=O)OC(C)(C)C)C=4C=CC=CC=4)C[C@]1(O)C3(C)C)=O)(C)[C@@H](O)C[C@H]1OC[C@]12OC(=O)C)C(=O)C1=CC=CC=C1 ZDZOTLJHXYCWBA-VCVYQWHSSA-N 0.000 claims description 2
- 229930012538 Paclitaxel Natural products 0.000 claims description 2
- 102000006601 Thymidine Kinase Human genes 0.000 claims description 2
- 239000000317 Topoisomerase II Inhibitor Substances 0.000 claims description 2
- 229940122803 Vinca alkaloid Drugs 0.000 claims description 2
- 125000004414 alkyl thio group Chemical group 0.000 claims description 2
- 229940100198 alkylating agent Drugs 0.000 claims description 2
- 239000002168 alkylating agent Substances 0.000 claims description 2
- 125000002947 alkylene group Chemical group 0.000 claims description 2
- 229940045799 anthracyclines and related substance Drugs 0.000 claims description 2
- 230000003432 anti-folate effect Effects 0.000 claims description 2
- 230000000340 anti-metabolite Effects 0.000 claims description 2
- 230000002927 anti-mitotic effect Effects 0.000 claims description 2
- 229940127074 antifolate Drugs 0.000 claims description 2
- 229940100197 antimetabolite Drugs 0.000 claims description 2
- 239000002256 antimetabolite Substances 0.000 claims description 2
- 239000003080 antimitotic agent Substances 0.000 claims description 2
- VSJKWCGYPAHWDS-FQEVSTJZSA-N camptothecin Chemical class C1=CC=C2C=C(CN3C4=CC5=C(C3=O)COC(=O)[C@]5(O)CC)C4=NC2=C1 VSJKWCGYPAHWDS-FQEVSTJZSA-N 0.000 claims description 2
- 229910052799 carbon Inorganic materials 0.000 claims description 2
- 229960004397 cyclophosphamide Drugs 0.000 claims description 2
- 230000001461 cytolytic effect Effects 0.000 claims description 2
- 229960003901 dacarbazine Drugs 0.000 claims description 2
- 230000006378 damage Effects 0.000 claims description 2
- 229960003957 dexamethasone Drugs 0.000 claims description 2
- 239000003534 dna topoisomerase inhibitor Substances 0.000 claims description 2
- 239000011737 fluorine Substances 0.000 claims description 2
- 239000004052 folic acid antagonist Substances 0.000 claims description 2
- 229910052736 halogen Inorganic materials 0.000 claims description 2
- 150000002367 halogens Chemical class 0.000 claims description 2
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims description 2
- 229960000485 methotrexate Drugs 0.000 claims description 2
- 229960003539 mitoguazone Drugs 0.000 claims description 2
- MXWHMTNPTTVWDM-NXOFHUPFSA-N mitoguazone Chemical compound NC(N)=N\N=C(/C)\C=N\N=C(N)N MXWHMTNPTTVWDM-NXOFHUPFSA-N 0.000 claims description 2
- 125000004043 oxo group Chemical group O=* 0.000 claims description 2
- 229960001592 paclitaxel Drugs 0.000 claims description 2
- WSDQIHATCCOMLH-UHFFFAOYSA-N phenyl n-(3,5-dichlorophenyl)carbamate Chemical compound ClC1=CC(Cl)=CC(NC(=O)OC=2C=CC=CC=2)=C1 WSDQIHATCCOMLH-UHFFFAOYSA-N 0.000 claims description 2
- 150000004885 piperazines Chemical class 0.000 claims description 2
- 150000003057 platinum Chemical class 0.000 claims description 2
- 230000005855 radiation Effects 0.000 claims description 2
- 229940066771 systemic antihistamines piperazine derivative Drugs 0.000 claims description 2
- 229940063683 taxotere Drugs 0.000 claims description 2
- BRNULMACUQOKMR-UHFFFAOYSA-N thiomorpholine Chemical group C1CSCCN1 BRNULMACUQOKMR-UHFFFAOYSA-N 0.000 claims description 2
- 229940044693 topoisomerase inhibitor Drugs 0.000 claims description 2
- 239000013603 viral vector Substances 0.000 claims description 2
- YNAVUWVOSKDBBP-UHFFFAOYSA-N Morpholine Chemical compound C1COCCN1 YNAVUWVOSKDBBP-UHFFFAOYSA-N 0.000 claims 2
- NQRYJNQNLNOLGT-UHFFFAOYSA-N Piperidine Chemical compound C1CCNCC1 NQRYJNQNLNOLGT-UHFFFAOYSA-N 0.000 claims 2
- GLVAUDGFNGKCSF-UHFFFAOYSA-N mercaptopurine Chemical compound S=C1NC=NC2=C1NC=N2 GLVAUDGFNGKCSF-UHFFFAOYSA-N 0.000 claims 2
- 102000015790 Asparaginase Human genes 0.000 claims 1
- 108010024976 Asparaginase Proteins 0.000 claims 1
- NOWKCMXCCJGMRR-UHFFFAOYSA-N Aziridine Chemical class C1CN1 NOWKCMXCCJGMRR-UHFFFAOYSA-N 0.000 claims 1
- GHASVSINZRGABV-UHFFFAOYSA-N Fluorouracil Chemical compound FC1=CNC(=O)NC1=O GHASVSINZRGABV-UHFFFAOYSA-N 0.000 claims 1
- VSNHCAURESNICA-UHFFFAOYSA-N Hydroxyurea Chemical compound NC(=O)NO VSNHCAURESNICA-UHFFFAOYSA-N 0.000 claims 1
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 claims 1
- 239000000365 Topoisomerase I Inhibitor Substances 0.000 claims 1
- CIUQDSCDWFSTQR-UHFFFAOYSA-N [C]1=CC=CC=C1 Chemical group [C]1=CC=CC=C1 CIUQDSCDWFSTQR-UHFFFAOYSA-N 0.000 claims 1
- 150000001335 aliphatic alkanes Chemical class 0.000 claims 1
- 229960003272 asparaginase Drugs 0.000 claims 1
- DCXYFEDJOCDNAF-UHFFFAOYSA-M asparaginate Chemical compound [O-]C(=O)C(N)CC(N)=O DCXYFEDJOCDNAF-UHFFFAOYSA-M 0.000 claims 1
- OYVAGSVQBOHSSS-WXFSZRTFSA-O bleomycin Chemical compound N([C@H](C(=O)N[C@H](C)[C@@H](O)[C@H](C)C(=O)N[C@@H]([C@H](O)C)C(=O)NCCC=1SC=C(N=1)C=1SC=C(N=1)C(=O)NCCC[S+](C)C)[C@@H](OC1C(C(O)C(O)C(CO)O1)OC1C(C(OC(N)=O)C(O)C(CO)O1)O)C=1NC=NC=1)C(=O)C1=NC([C@H](CC(N)=O)NC[C@H](N)C(N)=O)=NC(N)=C1C OYVAGSVQBOHSSS-WXFSZRTFSA-O 0.000 claims 1
- DQLATGHUWYMOKM-UHFFFAOYSA-L cisplatin Chemical compound N[Pt](N)(Cl)Cl DQLATGHUWYMOKM-UHFFFAOYSA-L 0.000 claims 1
- 229960004316 cisplatin Drugs 0.000 claims 1
- 125000001316 cycloalkyl alkyl group Chemical group 0.000 claims 1
- 229960002949 fluorouracil Drugs 0.000 claims 1
- 125000000623 heterocyclic group Chemical group 0.000 claims 1
- 125000002768 hydroxyalkyl group Chemical group 0.000 claims 1
- 229960001330 hydroxycarbamide Drugs 0.000 claims 1
- 229960001428 mercaptopurine Drugs 0.000 claims 1
- CFCUWKMKBJTWLW-BKHRDMLASA-N mithramycin Chemical compound O([C@@H]1C[C@@H](O[C@H](C)[C@H]1O)OC=1C=C2C=C3C[C@H]([C@@H](C(=O)C3=C(O)C2=C(O)C=1C)O[C@@H]1O[C@H](C)[C@@H](O)[C@H](O[C@@H]2O[C@H](C)[C@H](O)[C@H](O[C@@H]3O[C@H](C)[C@@H](O)[C@@](C)(O)C3)C2)C1)[C@H](OC)C(=O)[C@@H](O)[C@@H](C)O)[C@H]1C[C@@H](O)[C@H](O)[C@@H](C)O1 CFCUWKMKBJTWLW-BKHRDMLASA-N 0.000 claims 1
- 125000004430 oxygen atom Chemical group O* 0.000 claims 1
- 125000003386 piperidinyl group Chemical group 0.000 claims 1
- 229960003171 plicamycin Drugs 0.000 claims 1
- 239000011593 sulfur Substances 0.000 claims 1
- 125000004360 trifluorophenyl group Chemical group 0.000 claims 1
- 230000006698 induction Effects 0.000 abstract description 7
- 230000002459 sustained effect Effects 0.000 abstract 1
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 54
- 210000004027 cell Anatomy 0.000 description 46
- 239000000203 mixture Substances 0.000 description 33
- 102100021569 Apoptosis regulator Bcl-2 Human genes 0.000 description 31
- 238000000034 method Methods 0.000 description 30
- 101000971171 Homo sapiens Apoptosis regulator Bcl-2 Proteins 0.000 description 26
- 230000002829 reductive effect Effects 0.000 description 26
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 24
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 23
- CSNNHWWHGAXBCP-UHFFFAOYSA-L Magnesium sulfate Chemical compound [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 description 22
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 22
- 238000002844 melting Methods 0.000 description 16
- 230000008018 melting Effects 0.000 description 16
- 239000012074 organic phase Substances 0.000 description 16
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 15
- 239000011148 porous material Substances 0.000 description 15
- 230000008569 process Effects 0.000 description 15
- QLNJFJADRCOGBJ-UHFFFAOYSA-N propionamide Chemical compound CCC(N)=O QLNJFJADRCOGBJ-UHFFFAOYSA-N 0.000 description 15
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 14
- 238000002360 preparation method Methods 0.000 description 14
- 239000000741 silica gel Substances 0.000 description 14
- 229910002027 silica gel Inorganic materials 0.000 description 14
- 229930101283 tetracycline Natural products 0.000 description 14
- 102000005962 receptors Human genes 0.000 description 13
- 108020003175 receptors Proteins 0.000 description 13
- NOTFZGFABLVTIG-UHFFFAOYSA-N Cyclohexylethyl acetate Chemical compound CC(=O)OCCC1CCCCC1 NOTFZGFABLVTIG-UHFFFAOYSA-N 0.000 description 12
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 12
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 12
- 239000003480 eluent Substances 0.000 description 11
- 229910052943 magnesium sulfate Inorganic materials 0.000 description 11
- 235000019341 magnesium sulphate Nutrition 0.000 description 11
- 239000000243 solution Substances 0.000 description 11
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 11
- 230000000694 effects Effects 0.000 description 10
- FYSNRJHAOHDILO-UHFFFAOYSA-N thionyl chloride Chemical compound ClS(Cl)=O FYSNRJHAOHDILO-UHFFFAOYSA-N 0.000 description 10
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 9
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 9
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 9
- 210000001744 T-lymphocyte Anatomy 0.000 description 9
- 239000008346 aqueous phase Substances 0.000 description 9
- 230000030833 cell death Effects 0.000 description 9
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 8
- 239000012528 membrane Substances 0.000 description 8
- 101150017888 Bcl2 gene Proteins 0.000 description 7
- 239000004098 Tetracycline Substances 0.000 description 7
- 229960003529 diazepam Drugs 0.000 description 7
- AAOVKJBEBIDNHE-UHFFFAOYSA-N diazepam Chemical compound N=1CC(=O)N(C)C2=CC=C(Cl)C=C2C=1C1=CC=CC=C1 AAOVKJBEBIDNHE-UHFFFAOYSA-N 0.000 description 7
- 239000000706 filtrate Substances 0.000 description 7
- 238000003756 stirring Methods 0.000 description 7
- 229960002180 tetracycline Drugs 0.000 description 7
- OFVLGDICTFRJMM-WESIUVDSSA-N tetracycline Chemical compound C1=CC=C2[C@](O)(C)[C@H]3C[C@H]4[C@H](N(C)C)C(O)=C(C(N)=O)C(=O)[C@@]4(O)C(O)=C3C(=O)C2=C1O OFVLGDICTFRJMM-WESIUVDSSA-N 0.000 description 7
- 235000019364 tetracycline Nutrition 0.000 description 7
- 150000003522 tetracyclines Chemical class 0.000 description 7
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 6
- 238000001816 cooling Methods 0.000 description 6
- HPNMFZURTQLUMO-UHFFFAOYSA-N diethylamine Chemical compound CCNCC HPNMFZURTQLUMO-UHFFFAOYSA-N 0.000 description 6
- FKRCODPIKNYEAC-UHFFFAOYSA-N ethyl propionate Chemical compound CCOC(=O)CC FKRCODPIKNYEAC-UHFFFAOYSA-N 0.000 description 6
- 210000004408 hybridoma Anatomy 0.000 description 6
- 210000003470 mitochondria Anatomy 0.000 description 6
- 239000012071 phase Substances 0.000 description 6
- BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Chemical compound [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 description 6
- 238000001953 recrystallisation Methods 0.000 description 6
- 239000013598 vector Substances 0.000 description 6
- TZCPCKNHXULUIY-RGULYWFUSA-N 1,2-distearoyl-sn-glycero-3-phosphoserine Chemical compound CCCCCCCCCCCCCCCCCC(=O)OC[C@H](COP(O)(=O)OC[C@H](N)C(O)=O)OC(=O)CCCCCCCCCCCCCCCCC TZCPCKNHXULUIY-RGULYWFUSA-N 0.000 description 5
- PMATZTZNYRCHOR-CGLBZJNRSA-N Cyclosporin A Chemical compound CC[C@@H]1NC(=O)[C@H]([C@H](O)[C@H](C)C\C=C\C)N(C)C(=O)[C@H](C(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)N(C)C(=O)CN(C)C1=O PMATZTZNYRCHOR-CGLBZJNRSA-N 0.000 description 5
- 229930105110 Cyclosporin A Natural products 0.000 description 5
- 108010036949 Cyclosporine Proteins 0.000 description 5
- ZAFNJMIOTHYJRJ-UHFFFAOYSA-N Diisopropyl ether Chemical compound CC(C)OC(C)C ZAFNJMIOTHYJRJ-UHFFFAOYSA-N 0.000 description 5
- 230000001640 apoptogenic effect Effects 0.000 description 5
- 238000002512 chemotherapy Methods 0.000 description 5
- XBDQKXXYIPTUBI-UHFFFAOYSA-N dimethylselenoniopropionate Natural products CCC(O)=O XBDQKXXYIPTUBI-UHFFFAOYSA-N 0.000 description 5
- 238000002474 experimental method Methods 0.000 description 5
- 239000000411 inducer Substances 0.000 description 5
- 239000011159 matrix material Substances 0.000 description 5
- 230000002093 peripheral effect Effects 0.000 description 5
- 102000004169 proteins and genes Human genes 0.000 description 5
- 238000001959 radiotherapy Methods 0.000 description 5
- LEINOXRFIYQSFV-ZPGRZCPFSA-N (3s)-n-[(2s)-6-amino-1-(2,2-diphenylethylamino)-1-oxohexan-2-yl]-2-(4-oxo-4-phenylbutanoyl)-3,4-dihydro-1h-isoquinoline-3-carboxamide Chemical compound C([C@H]1C(=O)N[C@@H](CCCCN)C(=O)NCC(C=2C=CC=CC=2)C=2C=CC=CC=2)C2=CC=CC=C2CN1C(=O)CCC(=O)C1=CC=CC=C1 LEINOXRFIYQSFV-ZPGRZCPFSA-N 0.000 description 4
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 4
- 108091006146 Channels Proteins 0.000 description 4
- ZWZWYGMENQVNFU-UHFFFAOYSA-N Glycerophosphorylserin Natural products OC(=O)C(N)COP(O)(=O)OCC(O)CO ZWZWYGMENQVNFU-UHFFFAOYSA-N 0.000 description 4
- PCLIMKBDDGJMGD-UHFFFAOYSA-N N-bromosuccinimide Chemical compound BrN1C(=O)CCC1=O PCLIMKBDDGJMGD-UHFFFAOYSA-N 0.000 description 4
- XBDQKXXYIPTUBI-UHFFFAOYSA-M Propionate Chemical compound CCC([O-])=O XBDQKXXYIPTUBI-UHFFFAOYSA-M 0.000 description 4
- 108010090931 Proto-Oncogene Proteins c-bcl-2 Proteins 0.000 description 4
- 102000013535 Proto-Oncogene Proteins c-bcl-2 Human genes 0.000 description 4
- 230000002424 anti-apoptotic effect Effects 0.000 description 4
- 239000006143 cell culture medium Substances 0.000 description 4
- 210000000170 cell membrane Anatomy 0.000 description 4
- 230000005764 inhibitory process Effects 0.000 description 4
- AWJUIBRHMBBTKR-UHFFFAOYSA-N isoquinoline Chemical compound C1=NC=CC2=CC=CC=C21 AWJUIBRHMBBTKR-UHFFFAOYSA-N 0.000 description 4
- 239000002244 precipitate Substances 0.000 description 4
- VZGDMQKNWNREIO-UHFFFAOYSA-N tetrachloromethane Chemical compound ClC(Cl)(Cl)Cl VZGDMQKNWNREIO-UHFFFAOYSA-N 0.000 description 4
- KKAFHPJEJHAIBO-UHFFFAOYSA-N 4-(bromomethyl)-2-phenylquinazoline Chemical compound N=1C2=CC=CC=C2C(CBr)=NC=1C1=CC=CC=C1 KKAFHPJEJHAIBO-UHFFFAOYSA-N 0.000 description 3
- 101100381516 Homo sapiens BCL2 gene Proteins 0.000 description 3
- 206010028851 Necrosis Diseases 0.000 description 3
- 229930193140 Neomycin Natural products 0.000 description 3
- KWYUFKZDYYNOTN-UHFFFAOYSA-M Potassium hydroxide Chemical compound [OH-].[K+] KWYUFKZDYYNOTN-UHFFFAOYSA-M 0.000 description 3
- 239000002253 acid Substances 0.000 description 3
- 150000001450 anions Chemical class 0.000 description 3
- 239000005557 antagonist Substances 0.000 description 3
- 238000013459 approach Methods 0.000 description 3
- 239000007864 aqueous solution Substances 0.000 description 3
- 125000003118 aryl group Chemical group 0.000 description 3
- 210000003719 b-lymphocyte Anatomy 0.000 description 3
- 230000033228 biological regulation Effects 0.000 description 3
- 239000011575 calcium Substances 0.000 description 3
- PFKFTWBEEFSNDU-UHFFFAOYSA-N carbonyldiimidazole Chemical compound C1=CN=CN1C(=O)N1C=CN=C1 PFKFTWBEEFSNDU-UHFFFAOYSA-N 0.000 description 3
- 238000004587 chromatography analysis Methods 0.000 description 3
- 230000001419 dependent effect Effects 0.000 description 3
- 239000012636 effector Substances 0.000 description 3
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 3
- 230000014509 gene expression Effects 0.000 description 3
- 230000001965 increasing effect Effects 0.000 description 3
- 239000003112 inhibitor Substances 0.000 description 3
- 150000002500 ions Chemical class 0.000 description 3
- 208000032839 leukemia Diseases 0.000 description 3
- 239000002609 medium Substances 0.000 description 3
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 3
- 230000017074 necrotic cell death Effects 0.000 description 3
- 229960004927 neomycin Drugs 0.000 description 3
- 230000037050 permeability transition Effects 0.000 description 3
- 230000000144 pharmacologic effect Effects 0.000 description 3
- 229910000027 potassium carbonate Inorganic materials 0.000 description 3
- 235000019260 propionic acid Nutrition 0.000 description 3
- 150000003254 radicals Chemical group 0.000 description 3
- 238000010992 reflux Methods 0.000 description 3
- FJUXXPWWWMLFJY-UHFFFAOYSA-N 1-(bromomethyl)-3-phenylisoquinoline Chemical compound C=1C2=CC=CC=C2C(CBr)=NC=1C1=CC=CC=C1 FJUXXPWWWMLFJY-UHFFFAOYSA-N 0.000 description 2
- ZOXOLPGKTSLTFP-UHFFFAOYSA-N 1-methyl-3-phenylisoquinoline Chemical compound C=1C2=CC=CC=C2C(C)=NC=1C1=CC=CC=C1 ZOXOLPGKTSLTFP-UHFFFAOYSA-N 0.000 description 2
- LTMRRSWNXVJMBA-UHFFFAOYSA-L 2,2-diethylpropanedioate Chemical compound CCC(CC)(C([O-])=O)C([O-])=O LTMRRSWNXVJMBA-UHFFFAOYSA-L 0.000 description 2
- 125000004182 2-chlorophenyl group Chemical group [H]C1=C([H])C(Cl)=C(*)C([H])=C1[H] 0.000 description 2
- SFARODKZVSNGEW-UHFFFAOYSA-N 3-(2-phenylquinazolin-4-yl)propanoic acid Chemical compound N=1C2=CC=CC=C2C(CCC(=O)O)=NC=1C1=CC=CC=C1 SFARODKZVSNGEW-UHFFFAOYSA-N 0.000 description 2
- VHYFNPMBLIVWCW-UHFFFAOYSA-N 4-Dimethylaminopyridine Chemical compound CN(C)C1=CC=NC=C1 VHYFNPMBLIVWCW-UHFFFAOYSA-N 0.000 description 2
- BRIQVMVBEYRTPX-UHFFFAOYSA-N 4-phenylnaphthalene-2-carboxylic acid Chemical compound C=12C=CC=CC2=CC(C(=O)O)=CC=1C1=CC=CC=C1 BRIQVMVBEYRTPX-UHFFFAOYSA-N 0.000 description 2
- 101710103970 ADP,ATP carrier protein Proteins 0.000 description 2
- 101710133192 ADP,ATP carrier protein, mitochondrial Proteins 0.000 description 2
- ZKHQWZAMYRWXGA-KQYNXXCUSA-J ATP(4-) Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](COP([O-])(=O)OP([O-])(=O)OP([O-])([O-])=O)[C@@H](O)[C@H]1O ZKHQWZAMYRWXGA-KQYNXXCUSA-J 0.000 description 2
- 206010000830 Acute leukaemia Diseases 0.000 description 2
- ZKHQWZAMYRWXGA-UHFFFAOYSA-N Adenosine triphosphate Natural products C1=NC=2C(N)=NC=NC=2N1C1OC(COP(O)(=O)OP(O)(=O)OP(O)(O)=O)C(O)C1O ZKHQWZAMYRWXGA-UHFFFAOYSA-N 0.000 description 2
- QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 2
- USFZMSVCRYTOJT-UHFFFAOYSA-N Ammonium acetate Chemical compound N.CC(O)=O USFZMSVCRYTOJT-UHFFFAOYSA-N 0.000 description 2
- 239000005695 Ammonium acetate Substances 0.000 description 2
- PAYRUJLWNCNPSJ-UHFFFAOYSA-N Aniline Chemical compound NC1=CC=CC=C1 PAYRUJLWNCNPSJ-UHFFFAOYSA-N 0.000 description 2
- 239000004342 Benzoyl peroxide Substances 0.000 description 2
- OMPJBNCRMGITSC-UHFFFAOYSA-N Benzoylperoxide Chemical compound C=1C=CC=CC=1C(=O)OOC(=O)C1=CC=CC=C1 OMPJBNCRMGITSC-UHFFFAOYSA-N 0.000 description 2
- DXJRLBKJXXVICK-UHFFFAOYSA-N C(CC)(=O)OCC.C1(=CC=CC=C1)C=1N=CC2=CC=CC=C2C1 Chemical compound C(CC)(=O)OCC.C1(=CC=CC=C1)C=1N=CC2=CC=CC=C2C1 DXJRLBKJXXVICK-UHFFFAOYSA-N 0.000 description 2
- KSFOVUSSGSKXFI-GAQDCDSVSA-N CC1=C/2NC(\C=C3/N=C(/C=C4\N\C(=C/C5=N/C(=C\2)/C(C=C)=C5C)C(C=C)=C4C)C(C)=C3CCC(O)=O)=C1CCC(O)=O Chemical compound CC1=C/2NC(\C=C3/N=C(/C=C4\N\C(=C/C5=N/C(=C\2)/C(C=C)=C5C)C(C=C)=C4C)C(C)=C3CCC(O)=O)=C1CCC(O)=O KSFOVUSSGSKXFI-GAQDCDSVSA-N 0.000 description 2
- 102000011727 Caspases Human genes 0.000 description 2
- 108010076667 Caspases Proteins 0.000 description 2
- 102100030497 Cytochrome c Human genes 0.000 description 2
- 108010075031 Cytochromes c Proteins 0.000 description 2
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 2
- 102000004190 Enzymes Human genes 0.000 description 2
- 108090000790 Enzymes Proteins 0.000 description 2
- 238000012413 Fluorescence activated cell sorting analysis Methods 0.000 description 2
- 101000611023 Homo sapiens Tumor necrosis factor receptor superfamily member 6 Proteins 0.000 description 2
- 108010067028 Mitochondrial Permeability Transition Pore Proteins 0.000 description 2
- 229920001213 Polysorbate 20 Polymers 0.000 description 2
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 2
- SMWDFEZZVXVKRB-UHFFFAOYSA-N Quinoline Chemical compound N1=CC=CC2=CC=CC=C21 SMWDFEZZVXVKRB-UHFFFAOYSA-N 0.000 description 2
- KEAYESYHFKHZAL-UHFFFAOYSA-N Sodium Chemical compound [Na] KEAYESYHFKHZAL-UHFFFAOYSA-N 0.000 description 2
- 241000713880 Spleen focus-forming virus Species 0.000 description 2
- HEDRZPFGACZZDS-MICDWDOJSA-N Trichloro(2H)methane Chemical compound [2H]C(Cl)(Cl)Cl HEDRZPFGACZZDS-MICDWDOJSA-N 0.000 description 2
- 108060008682 Tumor Necrosis Factor Proteins 0.000 description 2
- 102100040247 Tumor necrosis factor Human genes 0.000 description 2
- 102100040403 Tumor necrosis factor receptor superfamily member 6 Human genes 0.000 description 2
- 230000009471 action Effects 0.000 description 2
- 230000004913 activation Effects 0.000 description 2
- 238000013019 agitation Methods 0.000 description 2
- 235000019257 ammonium acetate Nutrition 0.000 description 2
- 229940043376 ammonium acetate Drugs 0.000 description 2
- 239000002246 antineoplastic agent Substances 0.000 description 2
- 235000019400 benzoyl peroxide Nutrition 0.000 description 2
- 230000004071 biological effect Effects 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 229960001265 ciclosporin Drugs 0.000 description 2
- 238000004040 coloring Methods 0.000 description 2
- 230000001120 cytoprotective effect Effects 0.000 description 2
- 238000001035 drying Methods 0.000 description 2
- 238000001704 evaporation Methods 0.000 description 2
- 230000008020 evaporation Effects 0.000 description 2
- 238000000684 flow cytometry Methods 0.000 description 2
- 238000001943 fluorescence-activated cell sorting Methods 0.000 description 2
- 239000007850 fluorescent dye Substances 0.000 description 2
- 238000013467 fragmentation Methods 0.000 description 2
- 238000006062 fragmentation reaction Methods 0.000 description 2
- 230000006870 function Effects 0.000 description 2
- 239000001963 growth medium Substances 0.000 description 2
- 230000002401 inhibitory effect Effects 0.000 description 2
- 238000009830 intercalation Methods 0.000 description 2
- 239000000155 melt Substances 0.000 description 2
- 210000001700 mitochondrial membrane Anatomy 0.000 description 2
- APRJFNLVTJWEPP-UHFFFAOYSA-M n,n-diethylcarbamate Chemical compound CCN(CC)C([O-])=O APRJFNLVTJWEPP-UHFFFAOYSA-M 0.000 description 2
- DUWWHGPELOTTOE-UHFFFAOYSA-N n-(5-chloro-2,4-dimethoxyphenyl)-3-oxobutanamide Chemical compound COC1=CC(OC)=C(NC(=O)CC(C)=O)C=C1Cl DUWWHGPELOTTOE-UHFFFAOYSA-N 0.000 description 2
- 230000002018 overexpression Effects 0.000 description 2
- 230000037361 pathway Effects 0.000 description 2
- 239000003208 petroleum Substances 0.000 description 2
- 239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 description 2
- XJMOSONTPMZWPB-UHFFFAOYSA-M propidium iodide Chemical compound [I-].[I-].C12=CC(N)=CC=C2C2=CC=C(N)C=C2[N+](CCC[N+](C)(CC)CC)=C1C1=CC=CC=C1 XJMOSONTPMZWPB-UHFFFAOYSA-M 0.000 description 2
- 229950003776 protoporphyrin Drugs 0.000 description 2
- RXWNCPJZOCPEPQ-NVWDDTSBSA-N puromycin Chemical compound C1=CC(OC)=CC=C1C[C@H](N)C(=O)N[C@H]1[C@@H](O)[C@H](N2C3=NC=NC(=C3N=C2)N(C)C)O[C@@H]1CO RXWNCPJZOCPEPQ-NVWDDTSBSA-N 0.000 description 2
- 239000011541 reaction mixture Substances 0.000 description 2
- 239000003642 reactive oxygen metabolite Substances 0.000 description 2
- 230000001105 regulatory effect Effects 0.000 description 2
- 239000012312 sodium hydride Substances 0.000 description 2
- 229910000104 sodium hydride Inorganic materials 0.000 description 2
- 239000002904 solvent Substances 0.000 description 2
- 238000009331 sowing Methods 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- QAOWNCQODCNURD-UHFFFAOYSA-N sulfuric acid Substances OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 2
- 230000002195 synergetic effect Effects 0.000 description 2
- 210000001519 tissue Anatomy 0.000 description 2
- XPNGNIFUDRPBFJ-UHFFFAOYSA-N (2-methylphenyl)methanol Chemical compound CC1=CC=CC=C1CO XPNGNIFUDRPBFJ-UHFFFAOYSA-N 0.000 description 1
- MZOFCQQQCNRIBI-VMXHOPILSA-N (3s)-4-[[(2s)-1-[[(2s)-1-[[(1s)-1-carboxy-2-hydroxyethyl]amino]-4-methyl-1-oxopentan-2-yl]amino]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-3-[[2-[[(2s)-2,6-diaminohexanoyl]amino]acetyl]amino]-4-oxobutanoic acid Chemical compound OC[C@@H](C(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@@H](N)CCCCN MZOFCQQQCNRIBI-VMXHOPILSA-N 0.000 description 1
- VZSRBBMJRBPUNF-UHFFFAOYSA-N 2-(2,3-dihydro-1H-inden-2-ylamino)-N-[3-oxo-3-(2,4,6,7-tetrahydrotriazolo[4,5-c]pyridin-5-yl)propyl]pyrimidine-5-carboxamide Chemical compound C1C(CC2=CC=CC=C12)NC1=NC=C(C=N1)C(=O)NCCC(N1CC2=C(CC1)NN=N2)=O VZSRBBMJRBPUNF-UHFFFAOYSA-N 0.000 description 1
- MQGPDJMHDFXMSC-UHFFFAOYSA-N 3-(3-phenylisoquinolin-1-yl)propanoic acid Chemical compound C=1C2=CC=CC=C2C(CCC(=O)O)=NC=1C1=CC=CC=C1 MQGPDJMHDFXMSC-UHFFFAOYSA-N 0.000 description 1
- YNSCKPCDFIDINW-UHFFFAOYSA-N 3-[[2-[[1-[2-(dimethylamino)acetyl]-6-methoxy-4,4-dimethyl-2,3-dihydroquinolin-7-yl]amino]-7h-pyrrolo[2,3-d]pyrimidin-4-yl]amino]thiophene-2-carboxamide Chemical compound COC1=CC(C(CCN2C(=O)CN(C)C)(C)C)=C2C=C1NC(N=C1NC=CC1=1)=NC=1NC=1C=CSC=1C(N)=O YNSCKPCDFIDINW-UHFFFAOYSA-N 0.000 description 1
- RUQIUASLAXJZIE-UHFFFAOYSA-N 3-methoxybenzoyl chloride Chemical compound COC1=CC=CC(C(Cl)=O)=C1 RUQIUASLAXJZIE-UHFFFAOYSA-N 0.000 description 1
- OTLNPYWUJOZPPA-UHFFFAOYSA-N 4-nitrobenzoic acid Chemical compound OC(=O)C1=CC=C([N+]([O-])=O)C=C1 OTLNPYWUJOZPPA-UHFFFAOYSA-N 0.000 description 1
- XYJODUBPWNZLML-UHFFFAOYSA-N 5-ethyl-6-phenyl-6h-phenanthridine-3,8-diamine Chemical compound C12=CC(N)=CC=C2C2=CC=C(N)C=C2N(CC)C1C1=CC=CC=C1 XYJODUBPWNZLML-UHFFFAOYSA-N 0.000 description 1
- CPCMRKSSTWXOIU-UHFFFAOYSA-N 7-phenyl-1-benzothiophene-2-carboxylic acid Chemical compound C=12SC(C(=O)O)=CC2=CC=CC=1C1=CC=CC=C1 CPCMRKSSTWXOIU-UHFFFAOYSA-N 0.000 description 1
- 229930024421 Adenine Natural products 0.000 description 1
- GFFGJBXGBJISGV-UHFFFAOYSA-N Adenine Chemical compound NC1=NC=NC2=C1N=CN2 GFFGJBXGBJISGV-UHFFFAOYSA-N 0.000 description 1
- 102000004875 Adenine Nucleotide Translocator 1 Human genes 0.000 description 1
- 108090001079 Adenine Nucleotide Translocator 1 Proteins 0.000 description 1
- IUCNQFHEWLYECJ-FNAJZLPOSA-L Atractyloside Chemical compound [K+].[K+].O1[C@H](CO)[C@@H](OS([O-])(=O)=O)[C@H](OS([O-])(=O)=O)[C@@H](OC(=O)CC(C)C)[C@@H]1O[C@H]1C[C@@]2(C)[C@@H]3CC[C@@H](C(=C)[C@@H]4O)C[C@]34CC[C@@H]2[C@H](C(O)=O)C1 IUCNQFHEWLYECJ-FNAJZLPOSA-L 0.000 description 1
- UHOVQNZJYSORNB-UHFFFAOYSA-N Benzene Chemical compound C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 description 1
- 108010006654 Bleomycin Proteins 0.000 description 1
- SVYYVVFXPAJGQR-UHFFFAOYSA-N C(CC)(=O)O.C1(=CC=CC=C1)C=1N=CC2=CC=CC=C2C1 Chemical compound C(CC)(=O)O.C1(=CC=CC=C1)C=1N=CC2=CC=CC=C2C1 SVYYVVFXPAJGQR-UHFFFAOYSA-N 0.000 description 1
- 101100408464 Caenorhabditis elegans plc-1 gene Proteins 0.000 description 1
- 101100421200 Caenorhabditis elegans sep-1 gene Proteins 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- KLWPJMFMVPTNCC-UHFFFAOYSA-N Camptothecin Natural products CCC1(O)C(=O)OCC2=C1C=C3C4Nc5ccccc5C=C4CN3C2=O KLWPJMFMVPTNCC-UHFFFAOYSA-N 0.000 description 1
- 102000004420 Creatine Kinase Human genes 0.000 description 1
- 108010042126 Creatine kinase Proteins 0.000 description 1
- XDTMQSROBMDMFD-UHFFFAOYSA-N Cyclohexane Chemical compound C1CCCCC1 XDTMQSROBMDMFD-UHFFFAOYSA-N 0.000 description 1
- 108010048028 Cyclophilin D Proteins 0.000 description 1
- UHDGCWIWMRVCDJ-CCXZUQQUSA-N Cytarabine Chemical compound O=C1N=C(N)C=CN1[C@H]1[C@@H](O)[C@H](O)[C@@H](CO)O1 UHDGCWIWMRVCDJ-CCXZUQQUSA-N 0.000 description 1
- 230000005778 DNA damage Effects 0.000 description 1
- 231100000277 DNA damage Toxicity 0.000 description 1
- 229940124087 DNA topoisomerase II inhibitor Drugs 0.000 description 1
- IAZDPXIOMUYVGZ-WFGJKAKNSA-N Dimethyl sulfoxide Chemical compound [2H]C([2H])([2H])S(=O)C([2H])([2H])[2H] IAZDPXIOMUYVGZ-WFGJKAKNSA-N 0.000 description 1
- YQYJSBFKSSDGFO-UHFFFAOYSA-N Epihygromycin Natural products OC1C(O)C(C(=O)C)OC1OC(C(=C1)O)=CC=C1C=C(C)C(=O)NC1C(O)C(O)C2OCOC2C1O YQYJSBFKSSDGFO-UHFFFAOYSA-N 0.000 description 1
- VGGSQFUCUMXWEO-UHFFFAOYSA-N Ethene Chemical class C=C VGGSQFUCUMXWEO-UHFFFAOYSA-N 0.000 description 1
- 102000005548 Hexokinase Human genes 0.000 description 1
- 108700040460 Hexokinases Proteins 0.000 description 1
- OAKJQQAXSVQMHS-UHFFFAOYSA-N Hydrazine Chemical compound NN OAKJQQAXSVQMHS-UHFFFAOYSA-N 0.000 description 1
- 206010020772 Hypertension Diseases 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- 206010025323 Lymphomas Diseases 0.000 description 1
- 206010027476 Metastases Diseases 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- 108091093105 Nuclear DNA Proteins 0.000 description 1
- 101710163270 Nuclease Proteins 0.000 description 1
- 102000043276 Oncogene Human genes 0.000 description 1
- 108700020796 Oncogene Proteins 0.000 description 1
- 102000035195 Peptidases Human genes 0.000 description 1
- 108091005804 Peptidases Proteins 0.000 description 1
- 102100034943 Peptidyl-prolyl cis-trans isomerase F, mitochondrial Human genes 0.000 description 1
- 208000006664 Precursor Cell Lymphoblastic Leukemia-Lymphoma Diseases 0.000 description 1
- 239000004365 Protease Substances 0.000 description 1
- 239000012980 RPMI-1640 medium Substances 0.000 description 1
- 102000006382 Ribonucleases Human genes 0.000 description 1
- 108010083644 Ribonucleases Proteins 0.000 description 1
- 206010039491 Sarcoma Diseases 0.000 description 1
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 1
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
- OUUQCZGPVNCOIJ-UHFFFAOYSA-M Superoxide Chemical compound [O-][O] OUUQCZGPVNCOIJ-UHFFFAOYSA-M 0.000 description 1
- 101710183280 Topoisomerase Proteins 0.000 description 1
- 108060008683 Tumor Necrosis Factor Receptor Proteins 0.000 description 1
- 102000004962 Voltage-dependent anion channels Human genes 0.000 description 1
- 108090001129 Voltage-dependent anion channels Proteins 0.000 description 1
- 108010084455 Zeocin Proteins 0.000 description 1
- XJLXINKUBYWONI-DQQFMEOOSA-N [[(2r,3r,4r,5r)-5-(6-aminopurin-9-yl)-3-hydroxy-4-phosphonooxyoxolan-2-yl]methoxy-hydroxyphosphoryl] [(2s,3r,4s,5s)-5-(3-carbamoylpyridin-1-ium-1-yl)-3,4-dihydroxyoxolan-2-yl]methyl phosphate Chemical compound NC(=O)C1=CC=C[N+]([C@@H]2[C@H]([C@@H](O)[C@H](COP([O-])(=O)OP(O)(=O)OC[C@@H]3[C@H]([C@@H](OP(O)(O)=O)[C@@H](O3)N3C4=NC=NC(N)=C4N=C3)O)O2)O)=C1 XJLXINKUBYWONI-DQQFMEOOSA-N 0.000 description 1
- 239000013543 active substance Substances 0.000 description 1
- 229960000643 adenine Drugs 0.000 description 1
- 229940009456 adriamycin Drugs 0.000 description 1
- 239000000556 agonist Substances 0.000 description 1
- 229910021529 ammonia Inorganic materials 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 230000003042 antagnostic effect Effects 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 229940088710 antibiotic agent Drugs 0.000 description 1
- 229940034982 antineoplastic agent Drugs 0.000 description 1
- FYQXODZRNSCOTR-UHFFFAOYSA-N atractyloside Natural products O1C(CO)C(OS(O)(=O)=O)C(OS(O)(=O)=O)C(OC(=O)CC(C)C)C1OC1CC2(C)C3CCC(C(=C)C4O)CC34CCC2C(C(O)=O)C1 FYQXODZRNSCOTR-UHFFFAOYSA-N 0.000 description 1
- 229960001561 bleomycin Drugs 0.000 description 1
- OYVAGSVQBOHSSS-UAPAGMARSA-O bleomycin A2 Chemical compound N([C@H](C(=O)N[C@H](C)[C@@H](O)[C@H](C)C(=O)N[C@@H]([C@H](O)C)C(=O)NCCC=1SC=C(N=1)C=1SC=C(N=1)C(=O)NCCC[S+](C)C)[C@@H](O[C@H]1[C@H]([C@@H](O)[C@H](O)[C@H](CO)O1)O[C@@H]1[C@H]([C@@H](OC(N)=O)[C@H](O)[C@@H](CO)O1)O)C=1N=CNC=1)C(=O)C1=NC([C@H](CC(N)=O)NC[C@H](N)C(N)=O)=NC(N)=C1C OYVAGSVQBOHSSS-UAPAGMARSA-O 0.000 description 1
- HQABUPZFAYXKJW-UHFFFAOYSA-N butan-1-amine Chemical compound CCCCN HQABUPZFAYXKJW-UHFFFAOYSA-N 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 229940127093 camptothecin Drugs 0.000 description 1
- 150000003857 carboxamides Chemical class 0.000 description 1
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 1
- 230000001925 catabolic effect Effects 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 238000004113 cell culture Methods 0.000 description 1
- 230000003833 cell viability Effects 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 210000003169 central nervous system Anatomy 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 230000002759 chromosomal effect Effects 0.000 description 1
- 230000008045 co-localization Effects 0.000 description 1
- 239000002131 composite material Substances 0.000 description 1
- 239000012043 crude product Substances 0.000 description 1
- 238000002425 crystallisation Methods 0.000 description 1
- 230000008025 crystallization Effects 0.000 description 1
- 229930182912 cyclosporin Natural products 0.000 description 1
- 210000000172 cytosol Anatomy 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- UPQZOUHVTJNGFK-UHFFFAOYSA-N diethyl 2-methylpropanedioate Chemical compound CCOC(=O)C(C)C(=O)OCC UPQZOUHVTJNGFK-UHFFFAOYSA-N 0.000 description 1
- DWLVWMUCHSLGSU-UHFFFAOYSA-N dimethylcarbamic acid Chemical compound CN(C)C(O)=O DWLVWMUCHSLGSU-UHFFFAOYSA-N 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- VSJKWCGYPAHWDS-UHFFFAOYSA-N dl-camptothecin Natural products C1=CC=C2C=C(CN3C4=CC5=C(C3=O)COC(=O)C5(O)CC)C4=NC2=C1 VSJKWCGYPAHWDS-UHFFFAOYSA-N 0.000 description 1
- 230000003828 downregulation Effects 0.000 description 1
- 239000000975 dye Substances 0.000 description 1
- 230000008029 eradication Effects 0.000 description 1
- ZMMJGEGLRURXTF-UHFFFAOYSA-N ethidium bromide Chemical compound [Br-].C12=CC(N)=CC=C2C2=CC=C(N)C=C2[N+](CC)=C1C1=CC=CC=C1 ZMMJGEGLRURXTF-UHFFFAOYSA-N 0.000 description 1
- DQYBDCGIPTYXML-UHFFFAOYSA-N ethoxyethane;hydrate Chemical compound O.CCOCC DQYBDCGIPTYXML-UHFFFAOYSA-N 0.000 description 1
- WDCDAAMJNUHOIY-UHFFFAOYSA-N ethyl acetate;2-propan-2-yloxypropane Chemical compound CCOC(C)=O.CC(C)OC(C)C WDCDAAMJNUHOIY-UHFFFAOYSA-N 0.000 description 1
- RIFGWPKJUGCATF-UHFFFAOYSA-N ethyl chloroformate Chemical compound CCOC(Cl)=O RIFGWPKJUGCATF-UHFFFAOYSA-N 0.000 description 1
- 230000005284 excitation Effects 0.000 description 1
- 230000007717 exclusion Effects 0.000 description 1
- 239000000284 extract Substances 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- MHMNJMPURVTYEJ-UHFFFAOYSA-N fluorescein-5-isothiocyanate Chemical compound O1C(=O)C2=CC(N=C=S)=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 MHMNJMPURVTYEJ-UHFFFAOYSA-N 0.000 description 1
- 238000001215 fluorescent labelling Methods 0.000 description 1
- 229940124750 glucocorticoid receptor agonist Drugs 0.000 description 1
- 229940126013 glucocorticoid receptor antagonist Drugs 0.000 description 1
- 239000003850 glucocorticoid receptor antagonist Substances 0.000 description 1
- 231100000086 high toxicity Toxicity 0.000 description 1
- XMBWDFGMSWQBCA-UHFFFAOYSA-N hydrogen iodide Chemical compound I XMBWDFGMSWQBCA-UHFFFAOYSA-N 0.000 description 1
- 230000006951 hyperphosphorylation Effects 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 238000010348 incorporation Methods 0.000 description 1
- 230000000977 initiatory effect Effects 0.000 description 1
- 208000014674 injury Diseases 0.000 description 1
- 239000002198 insoluble material Substances 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- INQOMBQAUSQDDS-UHFFFAOYSA-N iodomethane Chemical compound IC INQOMBQAUSQDDS-UHFFFAOYSA-N 0.000 description 1
- 230000002427 irreversible effect Effects 0.000 description 1
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 210000002311 liver mitochondria Anatomy 0.000 description 1
- 210000004698 lymphocyte Anatomy 0.000 description 1
- 230000005427 lymphocyte apoptotic process Effects 0.000 description 1
- 208000003747 lymphoid leukemia Diseases 0.000 description 1
- 238000010369 molecular cloning Methods 0.000 description 1
- OFCCYDUUBNUJIB-UHFFFAOYSA-N n,n-diethylcarbamoyl chloride Chemical compound CCN(CC)C(Cl)=O OFCCYDUUBNUJIB-UHFFFAOYSA-N 0.000 description 1
- 230000006654 negative regulation of apoptotic process Effects 0.000 description 1
- 230000009826 neoplastic cell growth Effects 0.000 description 1
- 229930027945 nicotinamide-adenine dinucleotide Natural products 0.000 description 1
- 239000012299 nitrogen atmosphere Substances 0.000 description 1
- 238000000655 nuclear magnetic resonance spectrum Methods 0.000 description 1
- 102000039446 nucleic acids Human genes 0.000 description 1
- 108020004707 nucleic acids Proteins 0.000 description 1
- 150000007523 nucleic acids Chemical class 0.000 description 1
- 229940127084 other anti-cancer agent Drugs 0.000 description 1
- 230000035699 permeability Effects 0.000 description 1
- 239000002831 pharmacologic agent Substances 0.000 description 1
- CWCMIVBLVUHDHK-ZSNHEYEWSA-N phleomycin D1 Chemical compound N([C@H](C(=O)N[C@H](C)[C@@H](O)[C@H](C)C(=O)N[C@@H]([C@H](O)C)C(=O)NCCC=1SC[C@@H](N=1)C=1SC=C(N=1)C(=O)NCCCCNC(N)=N)[C@@H](O[C@H]1[C@H]([C@@H](O)[C@H](O)[C@H](CO)O1)O[C@@H]1[C@H]([C@@H](OC(N)=O)[C@H](O)[C@@H](CO)O1)O)C=1N=CNC=1)C(=O)C1=NC([C@H](CC(N)=O)NC[C@H](N)C(N)=O)=NC(N)=C1C CWCMIVBLVUHDHK-ZSNHEYEWSA-N 0.000 description 1
- IOUVKUPGCMBWBT-GHRYLNIYSA-N phlorizin Chemical class O[C@@H]1[C@H](O)[C@H](O)[C@@H](CO)O[C@H]1OC1=CC(O)=CC(O)=C1C(=O)CCC1=CC=C(O)C=C1 IOUVKUPGCMBWBT-GHRYLNIYSA-N 0.000 description 1
- 239000008363 phosphate buffer Substances 0.000 description 1
- 235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 description 1
- 229920000137 polyphosphoric acid Polymers 0.000 description 1
- 229940002612 prodrug Drugs 0.000 description 1
- 239000000651 prodrug Substances 0.000 description 1
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 238000000425 proton nuclear magnetic resonance spectrum Methods 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 229950010131 puromycin Drugs 0.000 description 1
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 1
- 238000011002 quantification Methods 0.000 description 1
- 125000002294 quinazolinyl group Chemical group N1=C(N=CC2=CC=CC=C12)* 0.000 description 1
- IUVKMZGDUIUOCP-BTNSXGMBSA-N quinbolone Chemical compound O([C@H]1CC[C@H]2[C@H]3[C@@H]([C@]4(C=CC(=O)C=C4CC3)C)CC[C@@]21C)C1=CCCC1 IUVKMZGDUIUOCP-BTNSXGMBSA-N 0.000 description 1
- 239000012429 reaction media Substances 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 230000022532 regulation of transcription, DNA-dependent Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 230000002441 reversible effect Effects 0.000 description 1
- 229920006395 saturated elastomer Polymers 0.000 description 1
- 230000009758 senescence Effects 0.000 description 1
- 230000011664 signaling Effects 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 238000003153 stable transfection Methods 0.000 description 1
- 238000010186 staining Methods 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 229940037128 systemic glucocorticoids Drugs 0.000 description 1
- CIHOLLKRGTVIJN-UHFFFAOYSA-N tert‐butyl hydroperoxide Chemical compound CC(C)(C)OO CIHOLLKRGTVIJN-UHFFFAOYSA-N 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 238000010361 transduction Methods 0.000 description 1
- 230000026683 transduction Effects 0.000 description 1
- 230000007704 transition Effects 0.000 description 1
- 230000008733 trauma Effects 0.000 description 1
- 102000003390 tumor necrosis factor Human genes 0.000 description 1
- 102000003298 tumor necrosis factor receptor Human genes 0.000 description 1
- 230000035899 viability Effects 0.000 description 1
- OGWKCGZFUXNPDA-XQKSVPLYSA-N vincristine Chemical compound C([N@]1C[C@@H](C[C@]2(C(=O)OC)C=3C(=CC4=C([C@]56[C@H]([C@@]([C@H](OC(C)=O)[C@]7(CC)C=CCN([C@H]67)CC5)(O)C(=O)OC)N4C=O)C=3)OC)C[C@@](C1)(O)CC)CC1=C2NC2=CC=CC=C12 OGWKCGZFUXNPDA-XQKSVPLYSA-N 0.000 description 1
- 229960004528 vincristine Drugs 0.000 description 1
- OGWKCGZFUXNPDA-UHFFFAOYSA-N vincristine Natural products C1C(CC)(O)CC(CC2(C(=O)OC)C=3C(=CC4=C(C56C(C(C(OC(C)=O)C7(CC)C=CCN(C67)CC5)(O)C(=O)OC)N4C=O)C=3)OC)CN1CCC1=C2NC2=CC=CC=C12 OGWKCGZFUXNPDA-UHFFFAOYSA-N 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
Definitions
- the present invention relates in particular to a combination product comprising at least one compound having an affinity for the mitochondrial receptor for bci odiazepincs, cl at least one agent inducing apoptosis for simultaneous, separate or spread over time, intended for treatment cancer.
- Another aspect of the present invention relates to the use of said compound and / or said combination product for the manufacture of a medicament intended to facilitate the induction of apoptosis.
- the methods currently used in the treatment of cancers are mainly radiotherapy and chemotherapy. These techniques consist in eradicating the identified tumor cells by means of localized irradiations or by means of pharmacological inducers of cell death.
- these therapeutic approaches are not specific only to tumor cells. In fact, the surrounding tissues are also eradicated and a very high toxicity is noted.
- an approach to treating cancer may lie in restoring these programs.
- apoptosis is characterized by three phases: An initiation phase where the various death stimuli take so-called “private” pathways to converge on a common functional phase, which ultimately leads to the degradation phase characterized by the biochemical manifestations characteristic of cell death.
- the cficctricc phase is covered by the transition pig of mitochondrial permeability, true senscur of cell death since its open or closed conformations determine the fate of the cells. These different conformations can be induced by many ligands of the components of this permeability transition pig.
- the mitochondrial permeability transition pore commonly called 5 mcga-channel or multi-conductance channel, participates in the regulation of the level of calcium in the matrix, of the pH, and of the transmembrane potential ( ⁇ m ) in the mitochondria.
- This pore therefore functions as a channel dependent on Ca 2 ′, voltage, pH and redox potential with several levels of conductance and little selectivity to ions (Zoratti et al 1995, Kinnally et al 1996, Bernardi et al 1996, and
- an increase in the volume of the matrix causes either a physical disturbance of the external mitrochondrial membrane then the dissipation of ⁇ m (Kluck et al 1997, Yang et ni 1997, and Vandcr Heiden et al 1997) , that is to say a disturbance of the external membrane and the dissipation of ⁇ M ' perennial, of the internal membrane simultaneously (Zamzami et al 1996 and Susin et al 1996 a).
- the authors postulated that the increase in the volume of the matrix, which precedes the reduction in ⁇ , could be controlled by the opening of the PT pore.
- the PT pig can operate at both a low and reversible level of conductance (which would cause an entry of ions and water inside the mitochondrial matrix), as well as at a high level of conductance. and irreversible (this
- the PT pore is a multiprotein complex formed at the contact site between the internal and external mitochondrial membranes. There is a co-localization of the PT pig and the Bcl-2 oncoprotein (De Jong et al 1994). The exact molecular composition of this pig remains an enigma.
- PT pore subunits could constitute pharmacological targets used to modulate apoptosis.
- PKI 1,195 (1- (2-chlorophenyl) -N-methyl-N- (1-methylpropyl) -3- isoquinoline carboxamide) is known to be a prototypical ligand antagonist of the peripheral benzodiazepinc receptor mBzR (Ripond and al 1991 and Joseph-Liauzun et al 1997). More particularly, WO 93/1 1771 relates to the use of molecules such as PK I 1 195 for the treatment of diseases of the central nervous system, in particular trauma.
- cancer therapy consists of the use of radiation therapy, chemotherapy, or a combination thereof. These two methods have harmful side effects that are very poorly tolerated by patients.
- pharmacological agents aimed at increasing the susceptibility of tumor cells to the induction of apoptosis, is very advantageous. Indeed, it allows the use of lower doses of chemo or radiotherapy products, which minimizes their side effects.
- the components having a strong affinity for the PT pore subunits, mentioned above, are the object of the present invention because they make it possible to facilitate apoptosis and therefore to use lower doses of products with strong side effects. It also improves the effectiveness of certain treatments.
- the present invention relates to a combination product comprising at least one compound having an affinity for the mitochondrial benzodiazepinc receptor, and at least one agent inducing apoptosis for simultaneous, separate or spread over time use, intended for the treatment cancer.
- cancer is used in a broad sense which includes all neoplasia (for example cancers, sarcomas, lymphomas and leukemias).
- Said compound is selected from several families of molecules having an affinity for the mitochondrial (peripheral) receptor for benzodiazepincs, preferably from the families of general formula I, II, 111, IV, and V described below. • In the family of isoquinolincs, the molecules of general formula 1 are chosen in particular:
- RI is a branched or linear C1-C6 lower alkyl group
- R2 is a branched or linear C1-C6 lower alkyl group
- R3 is a halogen atom such that Cl, F, Br, I, and R4 is a hydrogen or halogen atom, the groups RI, R2, R3, R4 being chosen independently of each other.
- said compound is PKI 1195 (commercially available from SIGMA under the reference C 0424) corresponding to the following formula; 1- (2-chlorophenyl) -N-methyl-N- (1-methylpropyl) -3-isoquinolinc carboxamide.
- A represents a nitrogen atom or a CH group
- V and W identical or different, represent hydrogen or halogen atoms
- Z is fixed in the ortho or para position with respect to B and represents a phenylc, thienyl, pyridyl, or phenylc radical substituted pamn or two substituents chosen from halogen atoms, alkyl and alkoxy groups containing 1 to 4 carbon atoms, trifluoromethyl or nitro groups, the chain -X- (CH 2 ) resort- (CHR) transit, - CONR
- R 2 is fixed in the ortho or para position with respect to D,
- R represents a hydrogen atom or an alkyl group containing I to 3 carbon atoms
- Ri and R 2 which are identical or different, represent a linear or branched alkyl group containing 1 to 6 carbon atoms, cycloalkylc comprising 3 to 6 carbon atoms, phenylc, phenylalkyle or cycloalkylalkyle of which the alkyl part contains 1 to 3 carbon atoms and the cycloalkyl part contains 3 to 6 carbon atoms, alkylc comprising 3 to 6 carbon atoms provided that the double bond is not located in position 1, 2 with respect to the nitrogen atom, Ri and R 2 can also form together with the nitrogen atom to which they are attached a pyrrolidine, piperidinc, morpholinc or thiomorpholine ring, X represents a group CH-R 3 , NR ⁇ , SO, SO_ or an oxygen or sulfur atom.
- R 3 represents a hydrogen atom or an alkyl group having 1 to 3 carbon atoms
- Ri represents an alkyl group having 1 to 3 carbon atoms
- m is 0 or 1
- n is 0, 1 or 2
- X represents a group SO, S0 2 or N-R_ ⁇
- the sum m + n is at least equal to 1
- a and B each represent a nitrogen atom and Z is in position para with respect to B
- X cannot represent the group CH-Rt
- A represents a group CH
- B represents a nitrogen atom
- Z is in position ortho with respect to B
- X represents an atom d oxygen
- R represents a hydrogen atom
- the sum m + n is different from 1 and with the exception of N, N-dimethylcarbamate of phenyl-2 quinolylc-4.
- the compounds of formula (II) correspond to one of the formulas (IIa) or (11b)
- Ri cl R / identical or different represent straight or branched chain alkyl groups of C 1-C4, cycloalkyl in which the alkyl part contains 1 to 3 carbon atoms and the cycloalkyl part contains 3 to 6 carbon or phenyl atoms,
- Ri and R 'can also form with the nitrogen atom to which they are attached a piperidinc cycle.
- ⁇ r represents a phenylc, thienylc or phenylc radical substituted by one or two substituents chosen from halogen atoms (fiuor, chlorine, bromine), alkyl or alkoxy groups containing 1 to 4 carbon atoms, nitro or trifluorophenylc, ⁇ represents a of the following sequences
- R is a linear or branched C 1 -C 6 alkyl group, a phenyl group, a cycloalkyl group having C3-C6, a phenylalkyl or cycloalkyl group in which the alkyl radical contains C1-C3, or a group
- Rj and Rj are hydrogen atoms or alkyl groups and Rj is an alkenyl or alkynyl group, the sum of the carbon atoms in R 3 , Ri, and R5 being between 2 and 5,
- R 2 is a linear or branched C1-C6 alkyl group, a phenylalkyl or cycloalkyl group in which the alkyl radical contains C1-C3, a group
- R 3 , j, and R 5 are defined as above, or a group
- RI and R2 can form, together with the nitrogen atom to which they are attached, a 5, 6 or 7-membered heteroeyel radical which may contain another heteroatom chosen from nitrogen and oxygen and being able to carry one or two substituents chosen from C1-C3 alkyl, hydroxy, oxo, hydroxyalkylc, dimethylaminoalkylc, the alkyl part of which is C 1-C3, Z is a phenylc, pyridyl, thicnyl group, 2- thiazolylc or a phenyl group substituted by one or two substituents chosen from halogen atoms, alkyl, alkoxy, C 1 -C 3 alkylthio groups, trifluoromethyl group, and nitro group, 1 1
- X and Y are the same or different and are hydrogen or halogen atoms, C1-C3 alkyl or alkoxy groups, nitro or trifluoromethyl groups,
- a and B are independently nitrogen atoms or CM groups, or any stereoisomer of formula IV.
- EP 1 12 776B 1 has a particularly high affinity for the mitochondrial benzodiazepine receptor (EP 1 12 776B 1 page 21).
- R 1 and R 2 independently represent a linear or branched C1 -C6 alkyl group, a C3-C7 cycloalkyl group, a phenylalkyl or cycloalkyl group, the csi alkyl part of C 1 -C3; Ri and R 2 may also represent an alkenyl or alkynyl group of C2-C6 provided that the double or triple bond is not located in position 1 -2 relative to the nitrogen atom; Ri and R 2 can represent a group of formula -R 3 -Z -RA in which R 3 is a linear or branched alkylene group of C2-C6 provided that at least two carbon atoms separate the nitrogen atom from the group Z; R4 represents a C 1 -C 4 alkyl group and Z represents the oxygen or sulfur atom or the N-Rj group, Rj represents the hydrogen atom or a C 1 -C3 alkyl group; RI cl R2 can form with the nitrogen atom to which they are attached
- Ar represents a phenyl, pyridyl, or thienyl group or a phenyl group substituted by one or two substituents chosen from halogen atoms, C1-C4 alkyl, alkoxy and alkylthio groups, the trifluoromethyl group and the nitro group;
- a and B are independently N or CH.
- X, Y independently represents the hydrogen atom, halogen, an alkyl or alkoxy group comprising of C1 -C3, the nitro or trifluoromethyl group.
- apoptosis-inducing agent means any substance which directly or indirectly affects the viability of a cell.
- Said apoptosis inducing agent of the present invention can be selected in particular from agents which damage DNA, iigands of the glucocorticoid receptor, or from second pro-apoptotic messengers. These agents can also be selected from those commonly used in the treatment of cancer.
- said second pro-apoptotic messenger is selected from glucocorticoid derivatives, from alkylating agents such as nitrogen mustards, for example cyclophosphamide, platinum complexes, for example cisplatinc, ethylene derivatives -imine, dimethanc sulfonoxy- alkancs, piperazine derivatives, among topoisomerase inhibitors such as topoisomerasc-II inhibitors, for example anthracyclines, pipodophyllotoxin such as etoposidc, topoisomerase inhibitors- I, for example the derivatives of camptothecinc, among the antimetabolites such as the antifolates, for example methotrexate, the antipurincs, for example 6-mccaptopurine, the antipyrimides, for example 5-fiuorouracilc, among the antimitotics such as the vinca -alkaloids, taxoids such as taxol, taxotere, and among
- said agent inducing apoptosis is chosen from gamma radiation, etoposidc, doxorubicinc, dexamelhasonc, ceramide such as ceramide CS, lonidaminc.
- ceramide such as ceramide CS
- lonidaminc Some of said anticancer agents are more particularly described in US 5,260,327 which relates to the use of lonidamine to treat metastases, in OJ 5017353 which relates to the use of lonidamine in combination with other anticancer agents, and in EP 291,151 , which describes the use of phlorizin derivatives.
- the product according to the present invention may also contain a viral vector which has a gene which codes for an enzyme which makes it possible to activate the abovementioned compounds and or agents, for example thymidine kinase.
- a viral vector which has a gene which codes for an enzyme which makes it possible to activate the abovementioned compounds and or agents, for example thymidine kinase.
- EP 41573 1 there are numerous patents relating to the use of suicide genes activated in specific tissues. Among these documents, incorporated in the description by reference, there are: EP 494776, EP 690129, EP 657540, and EP 657541 which relate in particular to the manufacture of a medicament comprising a vector which has a gene capable of catalyzing the passage of a pro-drug in active substance. More particularly, EP 657539 relates to the use of the thymidine kinase gene with cellular specificity for the treatment of cancer.
- the product of the present invention may also comprise one or more pharmaceutically acceptable vehicles.
- the present invention relates to the use of the product described above for the manufacture of a medicament intended for the treatment of cancer.
- said medicament is intended to induce the death of ct7 tumor cells or to facilitate apoptosis.
- the present invention also relates to the use of a compound having an affinity for the milochondrial benzodiazepinc receptor for the manufacture of a medicament intended for the treatment of cancer, in particular for facilitating the induction of apoptosis.
- a compound of the family corresponding to one of the general formulas 1, II, III, IV, and V described above, preferably a compound selected from the following molecules: l - (2-chlorophenyl) -N-methyl-N- (l-methylpropyl ) -3-isoquinolinc carboxamidc (PK I 1195), N, N-diethylcarbamate of 3-phenyl naphthylc-1,
- N-methyl N [1-methyl propyl] (2-chloro-phenyl) -l isoquinolineecarboxamide-3 for the manufacture of such a medicament.
- Bcl-2 is the prototypical representative of the family of oncogenes inhibitors of apoptosis which contributes both to the genesis of cancer and which is responsible for the difficulties in eradicating tumors. Most of the cytoprotective effects of Bcl-2 can be attributed to its ability to protect the integrity of the mitochondrial membranes (Boise et al 1997, Rccd et al 1997). It has been shown that bcl-2 stabilizes the itrochondrial membranes in different models of apoptosc (Zamzami et al 1995, cl Decaudain cl al 1997).
- Bcl-2 does not succeed in inhibiting apoptosis in certain cases, in particular apoptosis induced by diamide cl by activation of caspase (Yasuhara et al 1997, Strasscr et al 1995, and Huang et al 1997) .
- Bcl-2 is also overcome by treatment with a taxoid, such as paclitaxel (taxol), an agent which allows hyperphosphorylation of Bcl-2 (Haldar et al 1 95 and 1996), and which promotes the opening of the PT pore (Evtodicnki et al 1 96)
- a taxoid such as paclitaxel (taxol)
- Bcl-2 protects the isolated mitochondria against the opening of the PT pore induced by low doses of protoporphyrin IX, a ligand of mBzR, and this inhibition is suppressed by high doses of protoporphyrin IX (Marchetti et al 1996a). This suggests that a functional interaction exists between Bcl-2 and mBzR.
- the protection against opening of the PT pore, controlled by Bcl-2 is not overcome by increasing doses of the other target agents of the PT pig such as atractyloside, a ligand of the translocatcur of adenine. Since the binding of mBzR does not cause a negative regulation of the expression of Bcl-2 (Carayon et al 1996), it therefore appears likely that changes in conformation resulting from the binding of PKI 1195 in the complex composed by mBzR and the PT pore indirectly affects the stability of the mictochondrial membrane and thus overcomes the anti-apoptotic function of Bcl-2. Consequently, the binding of a compound having an affinity on the mitochondrial benzodiazepine receptor, belonging to families I, II, III, IV, and V, in particular PKI 1195, represents an interesting strategy in particular for overcoming resistance to chemotherapy and radiotherapy.
- FIG. 1 Sy ⁇ crgisinc between PKI 1195 and In cernmiric for the induction of apoptosis of t ymocytes.
- the ihymocytes were cultured for 4 hours in the presence of ceramide C "(25 ⁇ M), diazepam (100 ⁇ M), and / or PKI 1195 (100 ⁇ M).
- the graph ⁇ represents the level of apoptosc with on the abscissa the perturbation of A M ',,, (determined by DiOCc) and on the ordinate the generation of superoxide anion (determined with HE).
- Graph B represents the level of apoptosc with the exposure of phosphatidylserine on the abscissa on the surface of the plasma membrane (measured with FITC-annexin V) and the cell viability on the ordinate (exclusion of ethydium bromide) (EthBr). .
- the numbers denote the percentages of cells found in each quadrant.
- PK1 1195 facilitates the induction of apoptosis in CEM-C7 T cells of acute leukemia.
- the cells were cultured with 10 ⁇ M of etoposide, 1 ⁇ M of dcxamethasone (DEX), of RU24858, of RU38486, and / or with 75 ⁇ M of PK I 1195 for either 12 hours or 24 hours.
- This graph represents the determination of the frequency of DiOC 6 (3) low (HE-> Eth) low , of DiOC 6 (3) w (HE-> Eth) , 18h and hypoploid cells as described in the examples.
- the asterisks indicate a significant and significant improvement (p ⁇ 0.01) in the induction of apoptosis by PKI 1195 compared to the control cultures (cultivated in the absence of PKI 1195).
- the cell line of hybridomas of T cells 2B4.1 1 stably transfected with an SFFV.neo vector containing the human gene Bcl-2 (graph li) or containing only the gene for resistance to neomycinc (neo) (graph ⁇ ) were grown for 12 hours in the presence of dcxamethasone (1 ⁇ M), PK I 1195 (50 ⁇ M) or diazepam (50 ⁇ M), and the characters associated with apoptosis, mentioned supra, have been determined.
- the numbers in the black circles indicate the frequency of the subdiploid cells.
- FIG. 4 PKI 1195 improves the susceptibility to apoptosis in leukemic B WEII I 231 cells which over-express Bcl-2.
- the WEHI 23 1 cells either transfected with the control neomycin vector (neo, graph A), or transfected with a vector containing the human Bcl-2 gene (graph B) were treated by ⁇ irradiation, with doxorubicin (doxo), cyclosporine A (CsA), alone or in combination with PKI 1195 (40 ⁇ M) or with diazepam (40 ⁇ M). These graphs show the determination by flow cytometry of the parameters of apoptosis indicated. The asterisks show a significant effect (p ⁇ 0.001) dc PK 1 1 195.
- PKI 1 195 facilitates the induction of apoptosis by a variety of sti uli.
- PKI 1195 is the prototypical antagonist ligand of the mitochondrial benzodiazepine receptor mBzR (Ripond et al 1991 and Joscph-Liauzun et al 1997). Up to doses of 50 to 100 ⁇ M, PKI 1 195 does not show any toxic effect on various cell types including in particular thymocytes (see FIG. 1), the T cell CEM-C7 of acute leukemia 1 (see FIG. 2) , hybridomas of T cells 2B4. 1 1 (see FIG. 3), and the leukemic WEHI23 B cells 1 (see FIG. 4).
- PK I 1 195 appears to be the most effective of the co- inducers of apoptosis (relative efficacy: PK I 1195 greater than 4'-chlordiazepam>diazepam> Ro-5-4864), this result correlates with the antagonistic potential of these compounds on the mBzR receptor (Zisterer et al 1997).
- PK I 1195 (but not diazepam) facilitates the induction of apoptosis by glucocorticoid receptor agonists (which include dcxamethasone and RU24858, (see Figure 2). was highlighted when using RU38486 and PK I 1195 simultaneously.
- PK I 1 195 facilitates the induction of apoptosis in response to a very wide variety of substances and in many different cell types, in particular in primary and transformed cell lines of human and murinc origin (see Figures 2 to 4 ).
- PK I 1 195 facilitates the induction of mitocliondrial and post-mitochondrial changes associated with apoptosis
- PK I 1195 The synergism between PK I 1195 and several pro-apoptotic agents extends to everything that characterizes the phenomenon of apoptosis. These phenomena include the early loss of mitochondrial transmembrane potential (measured using the potential-sensitive DiOC 6 (3) dye), increased generation of reactive oxygen species (measured by conversion of hydroethidine in ethidinc catalyzed by suproxide anions (see FIGS. 1 to 4), the eradication of phosphatidylserine residues on the surface of the plasma membrane measured using anncxinc V conjugated to F1TC (see FIG.
- PKI 1195 overcomes the inhibition of apoptosis controlled by Bcl-2 in several different cell lines.
- Bcl-2 has cytoprotective effects thanks to its broad spectrum of action (Kroemer et al 1997b, and Decaudain et al 1997).
- the overexpression of Bcl-2 very significantly prevents the disturbance of ⁇ m , the production of superoxid anions, and the nuclear apoptosis induced by dcxamethasone in T cell hybridomas (see FIG. 3).
- Simultaneous treatment with PKI 1195 and an apoptogenic agent shows a hyperadditive effect facilitating apoptosis even in the presence of Bcl-2.
- PKI 1 195 makes it possible to restore the induction of apoptosis in cells overexpressing Bcl-2 at least partially. This effect was observed in two different cell types called hybridomas of T cells 2B4.1 1 (see Figure 3B) and B cells WEHI231 leukemia (see Figure 4B).
- PKI 1195 overcomes the protection conferred by Bcl-2 against glucocorticoids (see Figure 3B), against ⁇ irradiation, doxorubicin, cyclosporin A (see Figure 4B), and etoposide. This effect is also observed in the mitochondrion, the cell redox potential, and the nuclei (see Figures 3 and 4).
- the present invention relates to a new strategy for improving the susceptibility of cells by the induction of apoptosis.
- the compounds of the isoquinoline carboxamide family in particular a specific antagonist ligand for the mitochondrial benzodiazepine receptor (PKI 1195), facilitates the induction of disturbance of ⁇ ; , involvementBy various apoptotic effectors, in particular DNA damage ( ⁇ irradiation, etoposide, doxorubicin), binding of ligands to the glucocorticoid receptor (dexamethasone, RU24858), and the second pro-apoptotic messengers of the ceramide type, such than ceramide C8.
- PKI 1195 mitochondrial benzodiazepine receptor
- the compounds of the isoquinoline carboxamide family improve the induction of signals classics of apoptosis such as exposure of phosphatidylserine to the surface of cells and fragmentation of nuclear DNA.
- the mitochondrial benzodiazepine receptor has been shown to interact with many proteins involved in the formation and / or regulation of the PT pig (McEnery et al 1992 and Kinnally et al 1993).
- PKI 1 195 facilitates the opening of the PT pig induced by a tumor necrosis factor (TNF- ⁇ ) in L929 cells (Pastorino et al 1 96).
- PKI 1 195 makes it possible to facilitate the induction of apoptosis, which correlates with the induction of the dissipation of ⁇ m controlled by the PT pore.
- results of the experiments, implemented during the present invention demonstrate the strong association between the mitochondria, the redox potential, the plasma membrane and the characteristics of apoptosis, and demonstrate that PKI 1195 acts on a mitochondrial target. to facilitate the induction of apoptosis.
- This new property of the compounds of the isoquinoline carboxamide family represents an opportunity to overcome resistance to chemotherapy and radiotherapy and in particular to facilitate the induction of cell death.
- Fxc plc 1 Cells and cell cultures
- 1 1 were transfected with the SFFV.nco vector containing the human bcl-2 gene or only the neomycin (neo) resistance gene (Green et al 1994).
- WEHI231 leukemia B cells were transfected with the human bcl-2 gene or with a neo-control vector (Cuendc et al 1993) and the human CEM-C7.H2 T cells of lymphoblastic leukemia (Strasser-Wozak, 1 95) were cultured in RPMI 1640 containing 10 % FCS, antibiotics, and L-glutaminc.
- the abovementioned cells (5-10 ⁇ lOVml) were cultured in the presence of the indicated amount of PKI 1195, diazepam (Sigma), dexamethazone (1 ⁇ M, Sigma), RU24858 (1 ⁇ M, Roussel Uclaf), of the glucocorticoid receptor antagonist RU38486 (1 ⁇ M, Roussel Uclaf), doxorubicin (1 ⁇ g / ml, Pharmacia), etoposide (10 ⁇ MVml, Sigma), cytosine arabinoside (10 ⁇ g / ml, Upjohn ), cyclosporine A (10 ⁇ M, Sandoz), ceramide C8 (25 ⁇ M, Bio ol, Plymouth Meeting, PA), or treatment with ⁇ irradiation (10 Gy). After the indicated intervals, the cells were recovered, and the characteristics associated with apoptosis were tested.
- Example 3 Quantification of the parameters associated with apoptosis by flow cvtoinctric.
- Example 4 Process for the preparation of N, N-diétl ⁇ lcnrba ⁇ nntc of pl ⁇ cnyl-3 napl ⁇ tylc-1.
- Example 5 Process for the preparation of N, N-dictl ⁇ l ⁇ -methyl-phcnyl-2 ⁇ uinnzolinc-4 propanamide. 3 g of carbonyldiimidazole are added under nitrogen to a suspension of 2.67 g of ⁇ -methylphenyl-2-quinazoline-4-propanoic acid in 30 cm3 of anhydrous tetrahydrofuran. After 2 hours of stirring, 6 cm 3 of diethylamine are added and the mixture is stirred for a further 4 hours. 150 cm3 of water and 100 cm3 of ethyl acetate are added.
- a mixture of 15 g of 4-methyl-2-phenyl-quinazolinc, of 13.3 g of N-bromosuccinimide and of 1.65 g of benzoyl peroxide in 150 cm 3 of carbon tetrachloride is brought to 90 ° C. for 3 hours. Filtered, the filtrate is evaporated and the residue chromatographed on silica gel with a cyclohexane-ethyl acetate mixture (9-1 by volume) as eluent. 11 g of 4-bromomethyl-2-phenyl quinazoline are obtained, melting at 110 ° C.
- 4-methyl-2-phenyl quinazolinc can be obtained according to W.L.F. ARM ⁇ REGO, Fuscd pyrimidincs, quinazolines Part. I, p. 39, Intersciences Publishers (1967), incorporated into the description by reference.
- Example 6 Process for the preparation of N-methyl N-pl ⁇ cn ⁇ l pl ⁇ ényl-2 ⁇ uiua / .oliuc- 4 propanamide.
- the 2-phenyl-quinazoline-4-propanoic acid is prepared according to the following process;
- Example 7 Process for the preparation of N, N-dicthyl (4-nitro-phenyl) -2 ⁇ i ⁇ azolinc-4 propanamide.
- Example 5 The procedure is as in Example 5 from 1.35 g of (4-nitro-phenyl) -2-quinazoline-4 propanoic acid, 0.82 g of carbonyldiimidazole and 0.9 cm3 of diethylamine in 20 cm3 of anhydrous tetrahydrofuran. After chromatography on silica gel with ethyl acetate as eluent and recrystallization from ethyl acetate, 0.35 g of NN-diethyl (4-nitro-phenyl) -2 quinazolinc-4 propanamide is obtained, which is obtained 168 ° C.
- (4-Nitro-phenyl) -2 quinazolinc-4 propanoic acid is prepared according to the following process (EP 2100S4A1, example 1 1; p.23,1.20-p.24,1.24 together p.20, 1.6-14): A mixture of 3.34 g of para-nitrobenzoic acid and 20 cm 3 of thionyl chloride is brought to reflux for 3 hours. The excess thionyl chloride is removed by evaporation under reduced pressure and to the residual product is added 20 cm3 of chloroform, 5.5 cm3 of triethylamine and 2.21 g of ethyl (2-amino-bcnzoyl) -3 propionate. .
- Example 8 Process for the preparation of N, N-diélltyl [(pI ⁇ ényI-2 trifIuoro ⁇ néthyl-8 ⁇ i ⁇ oli ⁇ yl-4) oxy] -2 propanamide.
- Phenyl-2 trifiuoromethyl-8 hydroxy-4 quinoline can be prepared by action at 140 ° C of ethyl acetate (0.12 mole) on trifluoromethyl-2 aniline (0.12 mole) in the presence of polyphosphoric acid ( 86 g). It has a melting point of 136 ° C; (EP 210084 A1, example 84; p.72, 1.28 to p.73, 1.9 together p.55, 1. 1 - 14).
- Example 9 ⁇ Procedure for the preparation of NN-dietliyl 3-methoxy-3-plynyl) -2 qui ⁇ a / .olinc-4 propanamide.
- a mixture of 1.2 g of (3-methoxyphenyl) -2 quinazoline-4 ethyl propionate and 30 cm3 of diethylamine is heated at 250 ° C for 40 hours. After cooling, the excess diethylamine is evaporated. The residue is chromatographed on silica gel with a cyclohexane-ethyl acetate mixture (1-1 by volume) as eluent. The recovered product is recrystallized from isopropyl ether. 0.36 g of N, N-diethyl (3-methoxyphenyl) -2 quinazoline-4 propanamide is obtained, which melts at 87 ° C.
- the ethyl (3-melhoxyphenyl) -2 quinazolinc-4 propionate is prepared according to the following process:
- (2-Amino-benzoyl) -3-propionic acid can be prepared according to D.E. R1VETT et al., ⁇ ust. J. Chem., 24, 2717 (1971), incorporated into the description by reference.
- Example 10 Process for the preparation of N, N- ic ⁇ yl pl ⁇ én ⁇ l-3 isoqt ⁇ i ⁇ insuli ⁇ e-1 propanamide.
- the procedure is as in Example 9 from 6.1 g of 3-phenylisoquinoline-1 ethyl propionate and 30 cm3 of diethylamine.
- the crude product is purified by means of 4 successive chromatographies on silica gel using a cyclohexane-ethyl acetate mixture (7-3 by volume) as eluent.
- 1.4 g of N, N-diethyl phenyl-3 isoquinoline-1 propanamide are obtained, melting at 58 ° C.
- Ethyl phenyl-3 isoquinoline-1 propionate is prepared according to the following process:
- a mixture of 21 g of 1-methyl-3-phenyl isoquinoline, 30.6 g of N-bromosuccinimide and 1 g of benzoyl peroxide in 730 cm 3 of carbon tetrachloride is brought to the boil for 48 hours. After cooling, the filtrate is filtered and the filtrate is evaporated to dryness under reduced pressure. The residue is chromatographed on silica gel with a toluene-methanol mixture (98-2 by volume) as eluent. After crystallization from isopropyl ether, 1 1 g of 1-bromomethyl-3-phenyl isoquinoline is obtained, melting at 84 ° C.
- Example 11 Process for the preparation of N-methyl N- (methyl-1 propyl) phenyl-7 benzol blthiophenecarboxamide-5.
- the residue is chromatographed on silica gel using a cyclohexane-ethyl acetate mixture (50-50 by volume) as eluent.
- the fractions containing the product are combined, evaporated under reduced pressure and taken up in a mixture of water and ethyl ether.
- the organic phase is decanted, washed with water, dried over magnesium sulfate and evaporated under reduced pressure.
- the residue is stirred for 1 hour 30 minutes with 20 cm 3 of 40-60 ° petroleum ether, filtered and dried.
- N- (methyl-1 propyl) phenyl-7 benzo [b] thiophenecarboxamide-5 can be prepared as follows: Heated at 90 ° C for 2 hours 3 g of 7-phenyl benzo [b] thiophenecarboxylic acid-5 in 30 cm3 of toluene and 2.6 cm3 of thionyl chloride. It is evaporated under reduced pressure, then 30 cm 3 of toluene and 9.94 cm 3 of triethylamine are added to the residue. The mixture is stirred and 1.2 cm 3 of butanamine are added dropwise.
- the mixture is stirred for 1 hour at room temperature, the toluene is evaporated off under reduced pressure and the residue is taken up in methylene chloride and an aqueous solution of potassium carbonate. Agitation is carried out for 5 minutes, the organic phase is washed with water, dried over magnesium sulphate and evaporated under reduced pressure.
- Example 12 Process for the preparation of N, N-diethyl phenyl-3 nnphtalènccnrhoxnmidc-1.
- Phenyl-3 naphthalenecarboxylic acid-1 can be prepared according to the method described by FC BADDAR et al., J. Chem. Soc, 1959, 1009, incorporated into the description by reference.
- Example 13 Process for the preparation of N-methyl N [1-methyl propyll (2-chloro-phenvP-1 iso ⁇ uinoleinecflrboxamide-3.
- B Determination of the inhibition of the anti-apoptotic activity dependent on Bcl2 in a cell line overexpressing Bcl2 in a conditional manner.
- clones derived for example from the cell line NCI-H1299 obtained from ATCC
- selection agents such as, for example neomycin, hygromycin, zeocin or puromycin
- clones derived for example from the cell line NCI-H1299 obtained from ATCC
- clones derived for example from the cell line NCI-H1299 obtained from ATCC
- clones derived for example from the cell line NCI-H1299 obtained from ATCC
- clones which were found to be significantly less sensitive to apoptosis induced by a range of concentrations of agents inducing apoptosis in the absence than in the presence of tetracycline in the culture medium, that is to say when they overexpress the protein Bcl2 rather than when they do not overexpress it.
- the agents inducing apoptosis tested were for example adriamycin (10-100 ⁇ g / rnl), terbutyl-hydroperoxide (25-100 ⁇ M), vincristine (0.03-0.003 ⁇ g / ml) and camptothecin (0.01- 0.1 ⁇ g / ml).
- To quantify the induction of apoptosis it is possible, for example, to use the method for assaying apoptosis induced in a cell population described in A.
- One possible way of assaying the inhibition of anti-apoptotic activity in a cell line overexpressing Bcl2 conditionally by a treatment which may be, for example, the incorporation of a chemical compound, consists in quantifying, using for example the method described.
- A the percentage of apoptosis induced in a population of cells originating, for example, from one of the clones described above, in the following 4 situations:
- the chemical compound to be evaluated is incorporated into the cell culture medium at the same time as an apoptosis-inducing agent such as for example those mentioned above and the clone is cultured in the absence of tetracycline or anhydrotetracycline, c that is, it overexpresses the protein Bcl2. In this situation, the percentage of cells in PI apoptosis is determined.
- the compound is incorporated into the cell culture medium at the same time as the same apoptosis-inducing agent as that used in situation 1 and the clone is grown in the presence of tetracycline (1 ⁇ g / ml) or anhydrotetracycline (0.5 ⁇ g / ml), that is to say that it does not overexpress the protein Bcl2.
- the percentage of cells in apoptosis P3 is determined.
- the compound is incorporated into the cell culture medium in the absence of an apoptosis-inducing agent and the clone is cultured in the presence of tetracycline (1 ⁇ g / ml) or anhydrotetracycline (0.5 ⁇ g / ml), that is, it does not overexpress the Bcl2 protein. In this situation, the percentage of cells in apoptosis P4 is determined.
- R 100 x (P1-P2) / (P3-P4).
- R 0, the compound is not an inhibitor at the concentration tested.
- a series of results can be obtained from a range of concentration of compound to be evaluated.
- An inhibitory concentration of 50% or IC50 can be calculated mathematically from these results.
- Several compounds can be compared according to their IC50. We will say for example that a product A is twice as active as a product B if the IC50 of A is twice lower than the IC50 of B.
- the IC50 values can vary depending on the cell clone used , nature and concentration of the apoptosis inducer used.
- the compounds of families II, 111, IV exhibit activities which can be at least 5 times better than that presented by PKI 1 5.
- the compounds of Examples 4 to 12 described above exhibit activities greater than those demonstrated by the compound PKI 195.
- the compounds of general formula (II) the following compounds are preferred
- Taxol induces bcl-2 phosphorylation and death of prostate cancer cells. Cancer Research 56, 1253-1255.
- Mitochondria are excitable organelles capable of generating and conveying electric and calcium currents. Cell 89, 1145-1 153.
- Intracellular adenosine triphosphate (ATP) concentration a switch in the decision between apoptosis and necrosis. J. Exp. Med. 185, 1481 - 1486.
- ATP adenosine triphosphate
- Mitochondrial permeability transition is a central coordinating event of apoptosis. J. Exp. Med 184, 1155-1 160. Marchetti, P., Hirsch, T., Zamzami, N., Castedo, M., Decaudin, D., Susin, SA, Masse, B., and Kroemer, G. (1996b). Mitochondrial permeability transition triggers lymphocyte apoptosis. J. Immunol. 157, 4830-4836.
- Nicotera, P., and Leist, M. (1997). Energy supply and the shape of death in neurons and lymphoid cells. Cell Death Diff: 4, 435-442.
- Bcl-2 inhibits the mitochondrial release of an apoptogenic protease. J. Exp. Med. 184, 1331-1342.
Abstract
Description
Claims
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP99923718A EP1087790A2 (fr) | 1998-06-22 | 1999-06-11 | Utilisation d'un compose possedant une affinite pour le recepteur mitochondrial des benzodiazepines dans un medicament pour la therapie du cancer |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
FR9807864A FR2779963A1 (fr) | 1998-06-22 | 1998-06-22 | Utilisation d'un compose possedant une affinite pour le recepteur mitochondrial des benzodiazepines en therapie du cancer |
FR98/07864 | 1998-06-22 |
Publications (2)
Publication Number | Publication Date |
---|---|
WO1999066958A2 true WO1999066958A2 (fr) | 1999-12-29 |
WO1999066958A3 WO1999066958A3 (fr) | 2000-04-20 |
Family
ID=9527686
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/FR1999/001383 WO1999066958A2 (fr) | 1998-06-22 | 1999-06-11 | Utilisation d'un compose possedant une affinite pour le recepteur mitochondrial des benzodiazepines en therapie du cancer |
Country Status (6)
Country | Link |
---|---|
US (1) | US6319931B1 (fr) |
EP (1) | EP1087790A2 (fr) |
AU (1) | AU3508999A (fr) |
CA (1) | CA2274741A1 (fr) |
FR (1) | FR2779963A1 (fr) |
WO (1) | WO1999066958A2 (fr) |
Cited By (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
FR2808197A1 (fr) * | 2000-04-28 | 2001-11-02 | Centre Nat Rech Scient | Utilisation du compose ro5-4864 et de composes derives pour la preparation de medicaments destines au traitement des pathologies tumorales |
EP1423122A2 (fr) * | 2001-08-15 | 2004-06-02 | The Regents Of The University Of Michigan | Compositions et procedes relatifs a de nouveaux composes de benzodiazepine et leurs cibles |
US7638624B2 (en) | 2005-01-03 | 2009-12-29 | The Regents Of The University Of Michigan | Compositions and methods relating to novel benzodiazepine compounds and derivatives |
US7683046B2 (en) | 1999-04-30 | 2010-03-23 | The Regents Of The University Of Michigan | Benzodiazepine compositions for treating epidermal hyperplasia and related disorders |
US9849138B2 (en) | 2009-11-17 | 2017-12-26 | The Regents Of The University Of Michigan | 1,4-benzodiazepone-2,5-diones and related compounds with therapeutic properties |
Families Citing this family (31)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7125866B1 (en) * | 1999-04-30 | 2006-10-24 | Regents Of The University Of Michigan | Therapeutic applications of pro-apoptotic benzodiazepines |
US6380183B1 (en) * | 1998-12-18 | 2002-04-30 | Scios, Inc. | Treatment of diseases involving cyst formation |
US20050113460A1 (en) * | 1999-04-30 | 2005-05-26 | The Regents Of The University Of Michigan | Compositions and methods relating to novel compounds and targets thereof |
US7144880B2 (en) * | 1999-04-30 | 2006-12-05 | Regents Of The University Of Michigan | Compositions relating to novel compounds and targets thereof |
AU2002323528C1 (en) * | 2001-09-04 | 2009-11-12 | Texas Tech University | Multi-use multimodal imaging chelates |
WO2004108681A1 (fr) | 2003-06-06 | 2004-12-16 | Fibrogen, Inc. | Composes heteroaryliques contenant de l'azote et leur utilisation dans l'augmentation de l'erythropoietine endogene |
US20050272723A1 (en) * | 2004-04-27 | 2005-12-08 | The Regents Of The University Of Michigan | Methods and compositions for treating diseases and conditions associated with mitochondrial function |
US20060052369A1 (en) * | 2004-09-07 | 2006-03-09 | The Regents Of The University Of Michigan | Compositions and methods relating to novel compounds and targets thereof |
US20070043033A1 (en) * | 2005-06-01 | 2007-02-22 | The Regents Of The University Of Michigan | Unsolvated benzodiazepine compositions and methods |
US20070105844A1 (en) * | 2005-10-26 | 2007-05-10 | Regents Of The University Of Michigan | Therapeutic compositions and methods |
AU2006308655B2 (en) | 2005-11-01 | 2010-09-23 | The Regents Of The University Of Michigan | Novel 1,4-benzodiazepine-2,5-diones with therapeutic properties |
WO2007090068A2 (fr) * | 2006-01-27 | 2007-08-09 | Fibrogen, Inc. | Composes de cyanoisoquinoleine et procedes d'utilisation de ceux-ci |
EP2016078B1 (fr) * | 2006-04-04 | 2016-06-15 | Fibrogen, Inc. | Composés de pyrrolo- et de thiazolopyridine comme modulateurs de hif |
US7759338B2 (en) * | 2006-04-27 | 2010-07-20 | The Regents Of The University Of Michigan | Soluble 1,4 benzodiazepine compounds and stable salts thereof |
EP2037741B1 (fr) | 2006-06-09 | 2013-11-27 | The Regents Of The University Of Michigan | Dérives de benzodiazépine utiles dans le traitement de pathologies sur une base immune, inflammatoire ou proliferative. |
BRPI0808653A2 (pt) | 2007-03-09 | 2014-08-19 | Univ Michigan | Composições e métodos referindo-se a novos compostos e alvos dos mesmos. |
WO2008124614A1 (fr) | 2007-04-06 | 2008-10-16 | Neurocrine Biosciences, Inc. | Antagonistes des récepteurs de l'hormone libérant la gonadotropine et procédés s'y rapportant |
CN101678007B (zh) * | 2007-04-06 | 2013-07-03 | 纽罗克里生物科学有限公司 | 促性腺激素释放激素受体拮抗剂及其制药用途 |
CA2698248C (fr) | 2007-09-14 | 2017-08-29 | The Regents Of The University Of Michigan | Derives acyles phenyles de guanidine comme inhibiteurs de la f1f0-atpase et leur utilisation |
CA2703005A1 (fr) | 2007-11-06 | 2009-05-14 | The Regents Of The University Of Michigan | Composes benzodiazepinone utiles dans le traitement d'affections de la peau |
JP5567573B2 (ja) | 2008-09-11 | 2014-08-06 | ザ リージェンツ オブ ザ ユニバーシティ オブ ミシガン | アリールグアニジンf1f0−atpアーゼ阻害剤およびそれと関連する方法 |
CN105037323A (zh) | 2008-11-14 | 2015-11-11 | 菲布罗根有限公司 | 作为hif羟化酶抑制剂的苯并噻喃衍生物 |
WO2010121164A2 (fr) | 2009-04-17 | 2010-10-21 | The Regents Of The University Of Michigan | Composés de 1,4-benzodiazépinone et leur utilisation dans le traitement du cancer |
GB0907284D0 (en) | 2009-04-28 | 2009-06-10 | Queen Mary & Westfield College | Compounds for inducing cellular apoptosis |
US8673897B2 (en) | 2009-09-18 | 2014-03-18 | The Regents Of The University Of Michigan | Benzodiazepinone compounds and methods of treatment using same |
AU2010322287B2 (en) | 2009-11-17 | 2014-04-03 | The Regents Of The University Of Michigan | 1,4-benzodiazepine-2,5-diones and related compounds with therapeutic properties |
NZ700760A (en) | 2012-03-09 | 2016-08-26 | Fibrogen Inc | 4 -hydroxy- isoquinoline compounds as hif hydroxylase inhibitors |
CN107382859B (zh) | 2012-07-16 | 2018-09-14 | 菲布罗根有限公司 | 脯氨酰羟化酶抑制剂的晶体形态 |
NZ704660A (en) | 2012-07-16 | 2017-10-27 | Fibrogen Inc | Process for making isoquinoline compounds |
US8883823B2 (en) | 2012-07-16 | 2014-11-11 | Fibrogen, Inc. | Crystalline forms of a prolyl hydroxylase inhibitor |
CA2899024C (fr) | 2013-01-24 | 2022-01-04 | Fibrogen, Inc. | Formes cristallines d'acide {[1-cyano-5-(4-chlorophenoxy)-4-hydroxy-isoquinoline-3-carbonyl]-amino}-acetique |
Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0210084A1 (fr) * | 1985-05-30 | 1987-01-28 | Rhone-Poulenc Sante | Amides, procédés pour leur préparation et médicaments les contenant |
-
1998
- 1998-06-22 FR FR9807864A patent/FR2779963A1/fr not_active Withdrawn
-
1999
- 1999-06-11 EP EP99923718A patent/EP1087790A2/fr not_active Withdrawn
- 1999-06-11 WO PCT/FR1999/001383 patent/WO1999066958A2/fr not_active Application Discontinuation
- 1999-06-14 US US09/332,152 patent/US6319931B1/en not_active Expired - Lifetime
- 1999-06-14 CA CA002274741A patent/CA2274741A1/fr not_active Abandoned
- 1999-06-16 AU AU35089/99A patent/AU3508999A/en not_active Abandoned
Patent Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0210084A1 (fr) * | 1985-05-30 | 1987-01-28 | Rhone-Poulenc Sante | Amides, procédés pour leur préparation et médicaments les contenant |
Non-Patent Citations (1)
Title |
---|
HIRSCH T. ET AL: "PK11195, a ligand of the mitochondrial benzodiazepine receptor, facilitates the induction of apoptosis and reverses Bcl-2-mediated cytoprotection" EXPERIMENTAL CELL RESEARCH (EXP. CELL RES.),15/06/1998, 241/2 (426-434), XP002098088 United States * |
Cited By (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7683046B2 (en) | 1999-04-30 | 2010-03-23 | The Regents Of The University Of Michigan | Benzodiazepine compositions for treating epidermal hyperplasia and related disorders |
FR2808197A1 (fr) * | 2000-04-28 | 2001-11-02 | Centre Nat Rech Scient | Utilisation du compose ro5-4864 et de composes derives pour la preparation de medicaments destines au traitement des pathologies tumorales |
EP1423122A2 (fr) * | 2001-08-15 | 2004-06-02 | The Regents Of The University Of Michigan | Compositions et procedes relatifs a de nouveaux composes de benzodiazepine et leurs cibles |
EP1423122A4 (fr) * | 2001-08-15 | 2008-12-10 | Univ Michigan | Compositions et procedes relatifs a de nouveaux composes de benzodiazepine et leurs cibles |
US7638624B2 (en) | 2005-01-03 | 2009-12-29 | The Regents Of The University Of Michigan | Compositions and methods relating to novel benzodiazepine compounds and derivatives |
US9849138B2 (en) | 2009-11-17 | 2017-12-26 | The Regents Of The University Of Michigan | 1,4-benzodiazepone-2,5-diones and related compounds with therapeutic properties |
Also Published As
Publication number | Publication date |
---|---|
EP1087790A2 (fr) | 2001-04-04 |
FR2779963A1 (fr) | 1999-12-24 |
CA2274741A1 (fr) | 1999-12-22 |
WO1999066958A3 (fr) | 2000-04-20 |
US6319931B1 (en) | 2001-11-20 |
AU3508999A (en) | 2000-01-06 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EP1087790A2 (fr) | Utilisation d'un compose possedant une affinite pour le recepteur mitochondrial des benzodiazepines dans un medicament pour la therapie du cancer | |
AU2006318212B2 (en) | Oncogenic ras-specific cytotoxic compound and methods of use thereof | |
EP0939654A1 (fr) | Association inhibiteurs de no synthase et piegeurs des formes reactives de l'oxygene | |
JP2008536853A (ja) | 癌治療のための、組み合わせ、方法および組成物 | |
CA3138197A1 (fr) | Composes ciblant des recepteurs hormonaux nucleaires anticancereux | |
EP2818170B1 (fr) | N-(4-((3-(2-amino-4-pyrimidinyl)-2-pyridine yl) oxy)phényl)-4-(4-méthyl-2-thiényl)-1-phthalazinamine à utiliser dans le traitement d'un cancer résistant aux agents antimitotiques | |
EP3160463A1 (fr) | Administration intermittente d'inhibiteur de mdm2 | |
AU2014344789B2 (en) | Pharmaceutical combinations for the treatment of cancer | |
ES2387535T3 (es) | Corroles para neuroprotección y neurosanación | |
MX2011005095A (es) | Tratamiento de proteinopatias usando un inhibidor de farnesil transferasa. | |
EP3319965B1 (fr) | Nouveaux composés utilisables dans le traitement ou la prévention de maladies cancéreuses | |
WO2021097046A1 (fr) | Composés ciblant des récepteurs hormonaux nucléaires anticancéreux | |
WO2002076975A1 (fr) | Derives chimiques et leur application comme agent antitelomerase | |
EP3641756B1 (fr) | Composés tricycliques utilisés comme inhibiteurs du cyp1 | |
US20090176888A1 (en) | Composition comprising phytosphingosine or derivative thereof | |
US11952349B2 (en) | Anti-cancer nuclear hormone receptor-targeting compounds | |
WO2001082969A2 (fr) | Medicaments destines au traitement des pathologies tumorales contenant le compose r05-4864 et un agent inducteur de l'apoptose | |
WO2024073328A2 (fr) | Procédés de traitement du cancer et compositions associées | |
WO2021046178A1 (fr) | Composés et méthodes de traitement du cancer | |
JP2005509670A (ja) | クルシアノン異性体とその使用法 | |
Kaur Saini et al. | Evaluación de la respuesta quimiopreventiva de dos inhibidores de la ciclooxigenasa 2, etoricoxib y diclofenaco en el cáncer de colon murino empleando las técnicas espectroscópicas FTIR Y NMR | |
JP2003335694A (ja) | イソ化ホップエキスを有効成分とする多剤耐性克服剤 | |
OA16756A (fr) | Utilisation de la 3-(R)-[3-(2methoxyphenylthio)-2-(S)-methyl-propyl]amino3,4-dihydro-2H-1,5-benzoxathiepine pour le traitement du cancer et en particulier pour la prévention et/ou le traitement des métastases cancéreuses. | |
WO2013037800A1 (fr) | Utilisation de la 3-(r)-[3-(2-methoxyphenylthio)-2-(s)-methyl-propyl]amino-3,4-dihydro-2h-1,5-benzoxathiepine pour le traitement du cancer et en particulier pour la prevention et/ou le traitement des metastases cancereuses |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A2 Designated state(s): JP |
|
AL | Designated countries for regional patents |
Kind code of ref document: A2 Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
DFPE | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101) | ||
AK | Designated states |
Kind code of ref document: A3 Designated state(s): JP |
|
AL | Designated countries for regional patents |
Kind code of ref document: A3 Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE |
|
WWE | Wipo information: entry into national phase |
Ref document number: 1999923718 Country of ref document: EP |
|
WWP | Wipo information: published in national office |
Ref document number: 1999923718 Country of ref document: EP |
|
WWW | Wipo information: withdrawn in national office |
Ref document number: 1999923718 Country of ref document: EP |